title: granulocytes

description: mouse cell sorted granulocytes

hyb_protocol: 10 µg of labeled aRNA from each cell type was hybridized to an Affymetrix® Mouse 430-2 GeneChip. Fragmentation of aRNA, hybridization, staining, and scanning of the GeneChip was carried out according to the manufacturer’s protocol.

source_name: granulocytes from bone marrow

label_protocol: The isolated RNA immediately underwent linear amplification using the TargetAmp™ 2-Round Aminoallyl-aRNA Amplification kit 1.0 (Epicentre Biotechnologies, Madison, WI). After amplification, the aminoallyl-aRNA was cleaned using an RNeasy kit (Qiagen, Venlo, The Netherlands) and concentration was determined by absorbance at 260 nm. Aminoallyl-aRNA was quick frozen in a dry ice ethanol bath and stored at -80 °C until labeled with biotin-X-X-NHS (Epicentre Biotechnologies). The labeling reaction was cleaned using the Minelute cleanup kit (Qiagen) and the concentration was determined.

extract_protocol: Cells were thawed, selected based on morphology, and 50 or 100 were packed into empty, washed zonae pellucidae for ease with handling. Individual cell-packed zonae pellucidae were transferred to 1.5 ml microcentrifuge tubes and snap frozen on liquid nitrogen and then stored at -80 °C. Total RNA was extracted from 50-200 cells from each cell type using TRIzol reagent (Invitrogen, Carlsbad, CA) with linear acrylamide (Ambion, Inc., Austin, TX) as a co-precipitant.

treatment_protocol: For the isolation of mature, differentiated granulocytes, BM cells were stained with the anti-Gr-1 antibody. Cells with high granularity and strong expression of Gr-1 were sorted as granulocytes. The purity of sorted granulocytes was 99.4%, as determined by morphology and Wright-Giemsa staining

tag: BDF1 9-week old female


title: IRF6 knockout, biological rep2

status: Public on Oct 01 2006

type: RNA

city: St. Louis

first: David

middle: Michael

last: Alvarado

state: MO

address: 4565 Scott Ave

department: Genetics

country: USA

institute: Washington University in St. Louis

description: Gene expression data from E17.5 mouse skin, IRF6 null

hyb_protocol: The resultant biotinylated cRNA was fragmented then hybridized to the GeneChip Mouse Genome 430 2.0 Array (45,000 probe sets used to analyze over 39,000 mouse transcripts and variants from over 34,000 well-characterized mouse genes; Affymetrix, Inc.).  The arrays were washed and stained using the Affymetrix Model 450 Fluidics Station

scan_protocol: GeneChips were scanned using the Affymetrix Model 3000 scanner

data_processing: Expression values were generated using the microarray suite (MAS) v5.0 software (Affymetrix, Inc)

label: biotin

molecule: total RNA

organism: Mus musculus

source_name: Skin from Irf6 null

label_protocol: Five micrograms of total RNA was processed for use on the microarray by using the Affymetrix GeneChip one-cycle target labeling kit (Affymetrix, Inc., Santa Clara, CA) according to the manufacturer’s recommended protocols

extract_protocol: Total RNA was isolated as recommended (RNeasy, Qiagen, Valencia, CA), except that tissue was treated with proteinase K (20 mg/ml) for 20 minutes at 55°C.

treatment_protocol: Skin from E17.5 mice was removed and flash frozen.

tag: Background

value: mixed genetic backgroud of C57Bl/6 and 129/SvJ

tag: Genotype

value: IRF6 null

tag: Age

value: Embryonic day 17.5


title: hematopoietic progenitor cells

city: Storrs

first: Xiuchun

last: Tian

state: CT

address: 1392 Storrs Rd. Unit 4243

department: Center for Regenerative Biology

institute: University of Connecticut

description: mouse cell sorted hematopoietic progenitor cells

hyb_protocol: 10 ?g of labeled aRNA from each cell type was hybridized to an Affymetrix? Mouse 430-2 GeneChip. Fragmentation of aRNA, hybridization, staining, and scanning of the GeneChip was carried out according to the manufacturer?s protocol.

data_processing: per chip per gene normalization

label: Aminoallyl-aRNA labeled wiht biotin-X-X-NHS (Epicentre Biotechnologies).

source_name: hematopoietic progenitor cells

label_protocol: The isolated RNA immediately underwent linear amplification using the TargetAmp? 2-Round Aminoallyl-aRNA Amplification kit 1.0 (Epicentre Biotechnologies, Madison, WI). After amplification, the aminoallyl-aRNA was cleaned using an RNeasy kit (Qiagen, Venlo, The Netherlands) and concentration was determined by absorbance at 260 nm. Aminoallyl-aRNA was quick frozen in a dry ice ethanol bath and stored at -80 ?C until labeled with biotin-X-X-NHS (Epicentre Biotechnologies). The labeling reaction was cleaned using the Minelute cleanup kit (Qiagen) and the concentration was determined.

extract_protocol: Cells were thawed, selected based on morphology, and 50 or 100 were packed into empty, washed zonae pellucidae for ease with handling. Individual cell-packed zonae pellucidae were transferred to 1.5 ml microcentrifuge tubes and snap frozen on liquid nitrogen and then stored at -80 ?C. Total RNA was extracted from 50-200 cells from each cell type using TRIzol reagent (Invitrogen, Carlsbad, CA) with linear acrylamide (Ambion, Inc., Austin, TX) as a co-precipitant.

treatment_protocol: For HSC and HPC isolation, c-Kit positive cells were first enriched by immuno-selection with CD117 micromagnetic beads (Miltenyi Biotec, Auburn, CA). Cells were then stained with FITC-conjugated anti-CD34, PE-conjugated anti-Sca-1, allophycocyanin (APC)-conjugated anti-c-Kit, and a PE-Cy7-conjugated lineage marker cocktail consisting of anti-Gr-1, CD11b, B220, CD3, CD4, CD8, and Ter119 monoclonal antibodies (BD PharMingen, San Diego, CA, and eBioscience, San Diego, CA). 4´,6-Diamidino-2-phenylindole, dihydrochloride (DAPI) was added for dead cell discrimination. Based on multi-color flow cytometric analysis, LT-HSC (CD34-LKS), ST-HSC (CD34+LKS) and HPC (LKS-) were sorted by using a MoFlo High-Speed Cell Sorter (Dakocytomation, Fort Collins, CO).

tag: BDF1 9 week old female


title: IRF6 knockout, biological rep3


title: F-IIP(NSIP)3_Cy3

city: Denver

first: Ivana

middle: V

last: Yang

state: CO

address: 1400 Jackson Street

department: Medicine

institute: National Jewish Health

description: Labeling, hybridization, and scanning done using Agilent reagents, hardware, and protocols

data_processing: Lowess normalization in Feature Extraction

organism: Homo sapiens

source_name: Lung, Familial Idiopathic Interstitial Pneumonia (F-IIP), Nonspecific Interstitial Pneumonia (NSIP)

tag: Tissue

value: lung

source_name: Universal Human Reference RNA (UHRR)

tag: Manufacturer

value: Stratagene;

tag: Catalog number


title: S-IIP(UIP)5_Cy3

source_name: Lung, Sporadic Idiopathic Interstitial Pneumonia (S-IIP), Usual Interstitial Pneumonia (UIP)


title: S-IIP(UIP)8_Cy3

tag: Genetics

value: Sporadic IIP

tag: Histology

value: Usual Interstitial Pneumonia


title: IRF6 wt, biological rep3

description: Gene expression data from E17.5 mouse skin, IRF6 wt

source_name: Skin from Irf6 wt

value: IRF6 wt


title: long-term repopulating Hematopoietic stem cells (LT-HSC)

hyb_protocol: 10 ?g of labeled aRNA from each cell type was hybridized to an Affymetrix? Mouse 430-2 GeneChip. Fragmentation of aRNA, hybridization, staining, and scanning of the GeneChip was carried out according to the manufacturer's protocol.


title: IRF6 wt, biological rep2


title: Silicon-Pathogen_vs_Silicon-supplemented_replicate_2

status: Public on Sep 30 2006

city: Jouy en Josas

first: Florian

last: Chain

address: Domaine de Vilvert

department: Institut Micalis

country: France

institute: INRA

description: Supplementary file contains data obtained after scan

hyb_protocol: Hybridization was performed following Agilent's oligonucleotide microarray hybridization user's manual and Agilent's in situ Hybridization Plus kit. A volume of 200 µL of combined Cy3- and Cy5-labeled cDNA targets were denatured at 98 °C for 3 min and cooled to room temperature. They were mixed with 50 µL of 10x control targets, followed by the addition of 250 µL of 2x hybridization buffer. The 500 µL of reaction mix was applied to each Agilent 44K Arabidopsis 3 microarray (37,537 features), and hybridized in a hybridization rotation oven at 60 °C for 17 h. The slides were disassembled in 6 x SSC, 0.005% Triton X-102, washed first with 6xSSC, 0.005% Triton X-102 for 10 min at room temperature, then with 0.1 xSSC, 0.005% Triton X-102 for 5 min on ice, and dried using a nitrogen-filled air gun.

scan_protocol: The arrays were scanned using a dual-laser DNA microarray scanner (Agilent). The data was then extracted from images with Agilent’s Feature Extraction software 7.5.

data_processing: The R software 2.3 and the LIMMA package were used to normalize the microarray data (loess method for within array normalization followed by quantile method for between arrays normalization)

organism: Arabidopsis thaliana

source_name: Diseased and Si supplemented Arabidopsis

tag: Arabidopsis thaliana col-0, inoculated with Erysiphe cichoracearum, with Si supplementation

source_name: Silicon supplemented Arabidopsis

tag: Arabidopsis thaliana col-0, non inoculated, with Si supplementation


title: Silicon-Supplemented_vs_Silicon-Pathogen_replicate_1


title: Silicon-Supplemented_vs_Silicon-Pathogen_replicate_3


title: F-IIP(NSIP)1_Cy5


title: Silicon-Pathogen_vs_Silicon-supplemented_replicate_3


title: F-IIP(NSIP)2_Cy5


title: S-IIP(NSIP)1_Cy3

source_name: Lung, Sporadic Idiopathic Interstitial Pneumonia (S-IIP), Nonspecific Interstitial Pneumonia (NSIP)


title: Silicon-supplemented_vs_Control_replicate_3

source_name: Control Arabidopsis

tag: Arabidopsis thaliana col-0, non inoculated, no Si supplementation


title: Pathogen_vs_Silicon-Pathogen_replicate_3

source_name: Diseased Arabidopsis

tag: Arabidopsis thaliana col-0, inoculated with Erysiphe cichoracearum, no Si supplementation


title: Silicon-supplemented_vs_Control_replicate_1


title: Pathogen_vs_Control_replicate_2


title: F-IIP(NSIP)1_Cy3

value: Stratagene


title: F-IIP(NSIP)2_Cy3


title: Silicon-Pathogen_vs_Silicon-supplemented_replicate_1


title: Pathogen_vs_Silicon-Pathogen_replicate_1


title: Silicon-Pathogen_vs_Pathogen_replicate_3


title: Silicon-supplemented_vs_Control_replicate_2


title: Control_vs_Silicon_supplemented_replicate_3

description: Supplementary file contains raw data obained after scan.

data_processing: The R software 2.3 and the LIMMA package were used to normalize the microarray data (loess method for within array normalization followed by quantile method for between arrays normalization).


title: Control_vs_Silicon_supplemented_replicate_2

hyb_protocol: •	The protocol and conditions used for hybridization, blocking and washing, including any post-processing steps such as staining: Hybridization was performed following Agilent's oligonucleotide microarray hybridization user's manual and Agilent's in situ Hybridization Plus kit. A volume of 200 µL of combined Cy3- and Cy5-labeled cDNA targets were denatured at 98 °C for 3 min and cooled to room temperature. They were mixed with 50 µL of 10x control targets, followed by the addition of 250 µL of 2x hybridization buffer. The 500 µL of reaction mix was applied to each Agilent 44K Arabidopsis 3 microarray (37,537 features), and hybridized in a hybridization rotation oven at 60 °C for 17 h. The slides were disassembled in 6 x SSC, 0.005% Triton X-102, washed first with 6xSSC, 0.005% Triton X-102 for 10 min at room temperature, then with 0.1 xSSC, 0.005% Triton X-102 for 5 min on ice, and dried using a nitrogen-filled air gun.


title: Silicon-Pathogen_vs_Pathogen_replicate_2


title: Control_vs_Silicon_supplemented_replicate_1


title: Pathogen_vs_Control_replicate_3

tag: Arabidopsis thaliana, non inoculated, no Si supplementation


title: Pathogen_vs_Control_replicate_1


title: Control_vs_Pathogen_replicate_3

tag: Arabidopsis thaliana col-0, inoculated with E. cichoracearum, no Si supplementation


title: Pfu gamma 120min replicate4

status: Public on Sep 28 2006

city: College Park

first: Jocelyne

last: DiRuggiero

state: MD

address: 3221 H.J. Patterson Hall

department: Cell Biology and Molecular Genetics

institute: University of Maryland

description: For each time point, 2 types of replicates were included: (i) technical replicates: each gene-specific PCR product was spotted at 2 spatially different locations onto the slides, (ii) biological replicates: each comparison was performed from 4 independently processed cultures and hybridized to 4 different slides (replicate 1 to 4) to account for inherent biological variation occurring independently of the experimental perturbations, giving a total of 8 data points per condition per gene.

hyb_protocol: Hybridization was carried out in a sealed Corning hybridization chamber (Acton, MA) at 60 C for 18 hours. For each experimental time point four slides, with at least two features per open reading frame (ORF), were hybridized producing 8 replicates or more per ORF.

scan_protocol: Slides were scanned using an Axon 4100a Genepix personal slide scanner and the Genepix software V5 (Axon, Union City, CA).

data_processing: The background-normalized intensities were normalized by median ratio normalization as follows: median values were calculated for the ratios of the intensities for the two channels, channel one was divided by the square root of the median and channel two was multiplied by the square root of the median. Ratio of fluorescence intensity between sample and reference RNA were calculated as log10 values

organism: Pyrococcus furiosus

source_name: Pfu irradiated

label_protocol: First strand cDNA synthesis and labeling was carried out with total RNA (3 g), 200U Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA), random hexamers, 0.5 mM dATP, dGTP, dCTP, 0.2mM dTTP and 0.3 mM Cy3-dUTP or Cy5-dUTP (Amersham Biosciences, Piscataway, NJ) for 110 min at 42 C. Labeled cDNAs were cleaned up with alkaline treatment and Cyscribe GFX columns (Amersham Biosciences) according to the manufacturer s instructions.

growth_protocol: Cells were grown in 100ml serum bottles at 90 C under anaerobic conditions in the absence of sulfur and with 100 M Na2WO4 and 0.5% (wt/vol) maltose

extract_protocol: Cultures were centrifuged at 4000xg for 4 min at 4 C and RNA was extracted from the pellet using the TRI reagent (SIGMA T9424, St Louis, MO) as previously described (Chomczynski and Sacchi 1987). RNA samples were analyzed with a Beckman DU640 spectrophotometer (Beckman Coulter, Fullerton, CA) and gel electrophoresis for quality and quantification.

treatment_protocol: Cultures grown to approximately 5x106 cells/ml were chilled to 4 C and exposed to 2,500 Gy of gamma radiation using a 26,000-curie (9.6x1014 Bq) 60Co gamma source at the University of Maryland College Park Gamma Test Facility, at a dose rate of 73 Gy/min. Cultures were further incubated at 90 C and samples for RNA extraction were taken 120 min. after the temperature of the cultures reached 90 C (DiRuggiero et al. 1997).

tag: P. furiosus (DSMZ 3638)  cells gamma irradiated

source_name: Pfu reference

treatment_protocol: Cultures were grown to approximately 5x106 cells/ml and RNA was immediately extracted.

tag: P. furiosus (DSMZ 3638)  cells non-irradiated


title: Pfu gamma 60min replicate3

treatment_protocol: Cultures grown to approximately 5x106 cells/ml were chilled to 4 C and exposed to 2,500 Gy of gamma radiation using a 26,000-curie (9.6x1014 Bq) 60Co gamma source at the University of Maryland College Park Gamma Test Facility, at a dose rate of 73 Gy/min. Cultures were further incubated at 90 C and samples for RNA extraction were taken 60 min. after the temperature of the cultures reached 90 C (DiRuggiero et al. 1997).


title: Pfu gamma 60min replicate4


title: Pfu gamma 120min replicate3


title: Pfu gamma 20min replicate4

treatment_protocol: Cultures grown to approximately 5x106 cells/ml were chilled to 4 C and exposed to 2,500 Gy of gamma radiation using a 26,000-curie (9.6x1014 Bq) 60Co gamma source at the University of Maryland College Park Gamma Test Facility, at a dose rate of 73 Gy/min. Cultures were further incubated at 90 C and samples for RNA extraction were taken 20 min. after the temperature of the cultures reached 90 C (DiRuggiero et al. 1997).


title: Control_vs_Pathogen_replicate_1

description: Supplementary file contain raw data obained after scan.


title: Pfu gamma 40min replicate2

treatment_protocol: Cultures grown to approximately 5x106 cells/ml were chilled to 4 C and exposed to 2,500 Gy of gamma radiation using a 26,000-curie (9.6x1014 Bq) 60Co gamma source at the University of Maryland College Park Gamma Test Facility, at a dose rate of 73 Gy/min. Cultures were further incubated at 90 C and samples for RNA extraction were taken 40 min. after the temperature of the cultures reached 90 C (DiRuggiero et al. 1997).


title: Pfu gamma 60min replicate2


title: Pfu reference replicate1


title: Pfu gamma 40min replicate3


title: Pfu gamma 120min replicate1


title: Silicon-Pathogen_vs_Pathogen_replicate_1


title: Pfu gamma 0min replicate3

treatment_protocol: Cultures grown to approximately 5x106 cells/ml were chilled to 4 C and exposed to 2,500 Gy of gamma radiation using a 26,000-curie (9.6x1014 Bq) 60Co gamma source at the University of Maryland College Park Gamma Test Facility, at a dose rate of 73 Gy/min. Cultures were further incubated at 90 C and samples for RNA extraction were taken 0 min. after the temperature of the cultures reached 90 C (DiRuggiero et al. 1997).


title: Pfu gamma 40min replicate1


title: Pfu gamma 20min replicate2

growth_protocol: Cells were grown in 100ml serum bottles at 90 degrees C under anaerobic conditions in the absence of sulfur and with 100 M Na2WO4 and 0.5% (wt/vol) maltose

treatment_protocol: Cultures grown to approximately 5x106 cells/ml were chilled to 4 degrees C and exposed to 2,500 Gy of gamma radiation using a 26,000-curie (9.6x1014 Bq) 60Co gamma source at the University of Maryland College Park Gamma Test Facility, at a dose rate of 73 Gy/min. Cultures were further incubated at 90 degrees C and samples for RNA extraction were taken 20 min after the temperature of the cultures reached 90 degrees C (DiRuggiero et al. 1997).

growth_protocol: Cultures were grown to approximately 5x106 cells/ml and RNA was immediately extracted.


title: Pfu gamma 60min replicate1


title: GN8treatment (WT)

city: Kawasaki

first: Hanae

last: Kaku

state: Kanagawa

address: 1-1-1, Higashi-Mita, Tama-ku

department: Life Sciences

country: Japan

institute: Meiji University

description: Rice suspension cultured cells (Oryza sativa L. cv. Nipponnbare) used for total RNA extraction were maintained using a modified N-6 medium and incubated on a rotary shaker at 25 C and 120 rpm in a dark. Cells were transferred to a fresh medium every week. Those cells 4 or 5 days after transfer to the new medium were used experiment.40mg of cultured rice cells were transferred to 1 ml of the fresh medium in a 2 ml centrifuge tube and pre-incubated for 30 min at 25 C on a thermomixer shaken at 750 rpm. N-acetylchitooctaose elicitor (100nM) was added to the culture medium and incubated for 3hr.Total RNA was extracted from rice cells by RNeasy Plant Mini Kit (QIAGEN Inc., Valencia, CA, USA).

data_processing: log10 ratio (NormCH1/NormCH2)

organism: Oryza sativa

source_name: GN8 treatment rice cell

tag: rice cell treated with GN8 for 3hr

source_name: Non treatment rice cell

tag: rice cell treated with DW for 3hr


title: LPS treatment (WT) color-swap

data_processing: log10 ratio (NormCH2/NormCH1)

tag: ice cell treated with DW for 3hr

source_name: LPS treatment rice cell

tag: rice cell treated with LPS for 3hr r


title: Pfu gamma 20min replicate3

treatment_protocol: Cultures grown to approximately 5x106 cells/ml were chilled to 4 C and exposed to 2,500 Gy of gamma radiation using a 26,000-curie (9.6x1014 Bq) 60Co gamma source at the University of Maryland College Park Gamma Test Facility, at a dose rate of 73 Gy/min. Cultures were further incubated at 90 C and samples for RNA extraction were taken 20 min after the temperature of the cultures reached 90 C (DiRuggiero et al. 1997).


title: Pfu reference replicate2


title: Pfu gamma 120min replicate2


title: Pfu gamma 40min replicate4


title: Control_vs_Pathogen_replicate_2


title: GN8treatment (WT) color-swap

source_name: non treatment rice cell


title: Pfu gamma 20min replicate1

hyb_protocol: Hybridization was carried out in a sealed Corning hybridization chamber (Acton, MA) at 60°C for 18 hours. For each experimental time point four slides, with at least two features per open reading frame (ORF), were hybridized producing 8 replicates or more per ORF.

label_protocol: First strand cDNA synthesis and labeling was carried out with total RNA (3µg), 200U Superscript II reverse transcriptase (Invitrogen, Carlsbad, CA), random hexamers, 0.5 mM dATP, dGTP, dCTP, 0.2mM dTTP and 0.3 mM Cy3-dUTP or Cy5-dUTP (Amersham Biosciences, Piscataway, NJ) for 110 min at 42°C. Labeled cDNAs were cleaned up with alkaline treatment and Cyscribe GFX columns (Amersham Biosciences) according to the manufacturer’s instructions.

growth_protocol: Cells were grown in 100ml serum bottles at 90°C under anaerobic conditions in the absence of sulfur and with 100µM Na2WO4 and 0.5% (wt/vol) maltose

extract_protocol: Cultures were centrifuged at 4000xg for 4 min at 4°C and RNA was extracted from the pellet using the TRI reagent (SIGMA T9424, St Louis, MO) as previously described (Chomczynski and Sacchi 1987). RNA samples were analyzed with a Beckman DU640 spectrophotometer (Beckman Coulter, Fullerton, CA) and gel electrophoresis for quality and quantification.

treatment_protocol: Cultures grown to approximately 5x106 cells/ml were chilled to 4°C and exposed to 2,500 Gy of gamma radiation using a 26,000-curie (9.6x1014 Bq) 60Co gamma source at the University of Maryland College Park Gamma Test Facility, at a dose rate of 73 Gy/min. Cultures were further incubated at 90°C and samples for RNA extraction were taken  20 min after the temperature of the cultures reached 90°C (DiRuggiero et al. 1997).


title: Pfu gamma 0min replicate2


title: Pathogen_vs_Silicon-Pathogen_replicate_2


title: Silicon-Supplemented_vs_Silicon-Pathogen_replicate_2


title: EC2005081602AA

status: Public on Sep 27 2006

city: Cambridge

first: Justin

last: Lamb

state: MA

address: Seven Cambridge Center

institute: Broad Institute

description: HL60 with vehicle (DMSO) for 6 h

data_processing: MAS 5.0

tag: perturbagen

value: small molecule

tag: type

value: control

tag: name

tag: concentration

tag: vehicle

value: DMSO

tag: duration

value: 6 h

tag: cell


title: EC2005081604AA

description: HL60 treated with estradiol (.00000001 M) for 6 h

value: treatment

value: estradiol


title: EC2005081605AA

description: HL60 treated with colforsin (.00005 M) for 6 h

value: colforsin


title: EC2005061004AA

description: MCF7 treated with alpha-estradiol (.00000001 M) for 6 h

value: alpha-estradiol


title: Pfu gamma 0min replicate1


title: EC2005033012AA

description: PC3 treated with fulvestrant (.000001 M) for 6 h

value: fulvestrant


title: EC2005033008AA

description: PC3 with vehicle (DMSO) for 6 h


title: EC2005030717AA

description: PC3 treated with mercaptopurine (.00001 M) for 6 h

value: mercaptopurine


title: EC2005033010AA

description: PC3 treated with alpha-estradiol (.00000001 M) for 6 h


title: EC2005030704AA

description: PC3 treated with resveratrol (.00005 M) for 6 h

value: resveratrol


title: EC2005061002AA

description: MCF7 with vehicle (DMSO) for 6 h


title: EC2005030706AA

description: PC3 treated with docosahexaenoic acid ethyl ester (.0001 M) for 6 h

value: docosahexaenoic acid ethyl ester


title: EC2005030702AA

description: PC3 with vehicle (DMSO) for 6 h


title: EC2005030718AA

description: PC3 treated with monastrol (.0001 M) for 6 h

value: monastrol


title: EC2005030721AA

description: MCF7 treated with monastrol (.0001 M) for 6 h


title: LPS treatment (WT)

tag: rice cell treated with LPS for 3hr


title: EC2005030716AA

description: PC3 treated with butirosin (.00001 M) for 6 h

value: butirosin


title: EC2005020916AA

description: MCF7 treated with tioguanine (.00001 M) for 6 h

value: tioguanine

value: medium


title: EC2005033011AA

description: PC3 treated with genistein (.00001 M) for 6 h

value: genistein


title: EC2005020917AA

description: MCF7 treated with W-13 (.00001 M) for 6 h

value: small molecule


title: EC2005030715AA

description: PC3 treated with estradiol (.00000001 M) for 6 h


title: EC2005020915AA

description: MCF7 treated with benserazide (.00001 M) for 6 h

value: benserazide


title: EC2005010703AA

description: SKMEL5 treated with valproic acid (.001 M) for 6 h

value: valproic acid

value: DMSO


title: EC2005030720AA

description: MCF7 with vehicle (DMSO) for 6 h

value: control

value: 6 h


title: EC2005010702AA

description: SKMEL5 with vehicle (DMSO) for 6 h


title: EC2005020914AA

description: MCF7 with vehicle (medium) for 6 h


title: EC2005030714AA

description: PC3 with vehicle (DMSO) for 6 h


title: EC2005010704AA

description: SKMEL5 treated with colchicine (.000001 M) for 6 h

value: treatment

value: colchicine


title: EC2005020912AA

description: MCF7 treated with paclitaxel (.0000001 M) for 6 h

value: paclitaxel


title: EC2005020918AA

description: MCF7 treated with colchicine (.0000001 M) for 6 h


title: EC2004120708AA

description: MCF7 with vehicle (DMSO) for 6 h


title: EC2004120710AA

description: MCF7 treated with monastrol (.00002 M) for 6 h


title: EC2004112411AA

description: MCF7 treated with geldanamycin (.000001 M) for 6 h

value: geldanamycin


title: EC2004112410AA


title: EC2004121704AA

description: MCF7 treated with resveratrol (.00005 M) for 6 h

value: resveratrol


title: EC2004112409AA

description: MCF7 treated with 5666823 (.0001 M) for 6 h


title: EC2004121711AA


title: EC2005010706AA

description: SKMEL5 treated with novobiocin (.0001 M) for 6 h

value: novobiocin


title: EC2004121703AA

description: MCF7 treated with nocodazole (.000001 M) for 6 h

value: nocodazole


title: EC2005020908AA

description: MCF7 with vehicle (DMSO) for 6 h


title: EC2004121706AA

description: MCF7 treated with 4,5-dianilinophthalimide (.00001 M) for 6 h


title: EC2005030703AA

description: PC3 treated with splitomicin (.00002 M) for 6 h

value: splitomicin


title: EC2005030705AA

description: PC3 treated with U0125 (.000001 M) for 6 h


title: EC2004121702AA

description: MCF7 with vehicle (DMSO) for 6 h


title: EC2005020910AA

description: MCF7 treated with genistein (.00001 M) for 6 h


title: EC2005010705AA

description: SKMEL5 treated with benserazide (.00001 M) for 6 h


title: EC2004121708AA

description: MCF7 with vehicle (DMSO) for 6 h


title: EC2005020911AA

description: MCF7 treated with pentamidine (.0001 M) for 6 h

value: pentamidine


title: EC2004112408AA

description: MCF7 with vehicle (DMSO) for 6 h


title: EC2004111111AA

description: MCF7 treated with butein (.00001 M) for 6 h

value: butein


title: EC2004111112AA

description: MCF7 treated with NU-1025 (.0001 M) for 6 h


title: EC2004111110AA

description: MCF7 treated with thalidomide (.0001 M) for 6 h

value: thalidomide


title: EC2004111108AA

description: MCF7 with vehicle (DMSO) for 6 h

value: small molecule


title: EC2004102605AA

description: MCF7 treated with nifedipine (.00001 M) for 6 h

value: nifedipine

value: ethanol


title: EC2004102606AA

description: MCF7 treated with arachidonic acid (.00001 M) for 6 h

value: arachidonic acid


title: EC2004111109AA

description: MCF7 treated with monastrol (.00002 M) for 6 h

value: monastrol

value: DMSO


title: EC2004102604AA

description: MCF7 treated with ciclosporin (.000001 M) for 6 h

value: treatment

value: ciclosporin

value: 6 h


title: EC2004111105AA

description: MCF7 treated with resveratrol (.00005 M) for 6 h


title: EC2004112404AA

description: MCF7 treated with 3-aminobenzamide (.01 M) for 6 h


title: EC2004102603AA

description: MCF7 treated with MK-886 (.000001 M) for 6 h


title: EC2004102602AA

description: MCF7 with vehicle (ethanol) for 6 h

value: control


title: EC2004111106AA

description: MCF7 treated with monastrol (.0001 M) for 6 h


title: EC2004111103AA

description: MCF7 treated with geldanamycin (.000001 M) for 6 h

value: geldanamycin


title: EC2004111116AA

description: PC3 treated with 4,5-dianilinophthalimide (.00001 M) for 6 h


title: EC2004112405AA

description: MCF7 treated with bucladesine (.00002 M) for 6 h

value: bucladesine


title: EC2004111114AA

description: PC3 with vehicle (DMSO) for 6 h


title: EC2005020902AA

description: PC3 with vehicle (DMSO) for 6 h


title: EC2004111102AA

description: MCF7 with vehicle (DMSO) for 6 h


title: EC2004112402AA

description: MCF7 with vehicle (DMSO) for 6 h


title: EC2004111104AA

description: MCF7 treated with arachidonyltrifluoromethane (.00001 M) for 6 h

value: arachidonyltrifluoromethane


title: EC2005020906AA

description: PC3 treated with dimethyloxalylglycine (.001 M) for 6 h

value: dimethyloxalylglycine


title: EC2004081916AA

description: MCF7 treated with tetraethylenepentamine (.0001 M) for 12 h

value: tetraethylenepentamine

value: medium


title: EC2004111117AA

description: PC3 treated with fisetin (.00005 M) for 6 h

value: fisetin


title: EC2004081914AA

description: MCF7 with vehicle (medium) for 12 h

value: small molecule


title: EC2005020904AA

description: PC3 treated with butein (.00001 M) for 6 h

value: butein


title: EC2005020905AA

description: PC3 treated with HNMPA-(AM)3 (.000005 M) for 6 h


title: EC2004081915AA

description: MCF7 treated with deferoxamine (.0001 M) for 12 h

value: deferoxamine


title: EC2004111124AA

description: SKMEL5 treated with 15-delta prostaglandin J2 (.00001 M) for 6 h

value: 15-delta prostaglandin J2


title: EC2004111120AA

description: SKMEL5 with vehicle (DMSO) for 6 h


title: EC2004073018AA

description: HL60 treated with monorden (.0000001 M) for 6 h

value: monorden


title: EC2004081917AA

description: MCF7 treated with copper sulfate (.0001 M) for 12 h

value: copper sulfate


title: EC2004073015AA

description: HL60 treated with gefitinib (.00001 M) for 6 h

value: treatment

value: gefitinib

value: DMSO


title: EC2004073011AA

description: ssMCF7 treated with fulvestrant (.000001 M) for 6 h

value: fulvestrant

value: 6 h


title: EC2004081918AA

description: MCF7 treated with novobiocin (.0001 M) for 12 h

value: novobiocin


title: EC2004073014AA

description: HL60 with vehicle (DMSO) for 6 h

value: control


title: EC2004073012AA

description: ssMCF7 treated with nordihydroguaiaretic acid (.000001 M) for 6 h

value: nordihydroguaiaretic acid


title: EC2004073004AA

description: SKMEL5 treated with wortmannin (.00000001 M) for 6 h

value: wortmannin


title: EC2004073016AA

description: HL60 treated with SC-58125 (.00001 M) for 6 h


title: EC2004073005AA

description: SKMEL5 treated with SC-58125 (.00001 M) for 6 h


title: EC2004071424AA

description: SKMEL5 treated with troglitazone (.00001 M) for 6 h

value: troglitazone


title: EC2004073008AA

description: ssMCF7 with vehicle (DMSO) for 6 h


title: EC2004073002AA

description: SKMEL5 with vehicle (DMSO) for 6 h


title: EC2004071416AA

description: ssMCF7 treated with tetraethylenepentamine (.0001 M) for 6 h

value: tetraethylenepentamine

value: medium


title: EC2004071418AA

description: ssMCF7 treated with copper sulfate (.0001 M) for 6 h

value: small molecule


title: EC2004071417AA

description: ssMCF7 treated with novobiocin (.0001 M) for 6 h


title: EC2004073006AA

description: SKMEL5 treated with staurosporine (.00000001 M) for 6 h

value: staurosporine


title: EC2004112412AA

description: MCF7 treated with LM-1685 (.00001 M) for 6 h


title: EC2004071414AA

description: ssMCF7 with vehicle (medium) for 6 h


title: EC2004073017AA

description: HL60 treated with 1,5-isoquinolinediol (.0001 M) for 6 h


title: EC2004071420AA

description: SKMEL5 with vehicle (DMSO) for 6 h


title: EC2004073003AA

description: SKMEL5 treated with 17-allylamino-geldanamycin (.000001 M) for 6 h


title: EC2004071421AA

description: SKMEL5 treated with LY-294002 (.00001 M) for 6 h


title: EC2004071412AA

description: SKMEL5 treated with iloprost (.000001 M) for 6 h

value: iloprost


title: EC2004073009AA

description: ssMCF7 treated with 17-allylamino-geldanamycin (.000001 M) for 6 h


title: EC2004071422AA

description: SKMEL5 treated with sodium phenylbutyrate (.0002 M) for 6 h

value: sodium phenylbutyrate


title: EC2004071415AA

description: ssMCF7 treated with valproic acid (.001 M) for 6 h

value: valproic acid


title: EC2004071423AA

description: SKMEL5 treated with indometacin (.0001 M) for 6 h

value: treatment

value: indometacin


title: EC2004071411AA

description: SKMEL5 treated with pirinixic acid (.0001 M) for 6 h

value: pirinixic acid

value: DMSO


title: EC2004071408AA

description: SKMEL5 with vehicle (DMSO) for 6 h

value: 6 h


title: EC2004071410AA

description: SKMEL5 treated with fluphenazine (.00001 M) for 6 h

value: fluphenazine


title: EC2004071409AA

description: SKMEL5 treated with monorden (.0000001 M) for 6 h

value: monorden


title: EC2004071404AA

description: MCF7 treated with fluphenazine (.00001 M) for 6 h


title: EC2004071406AA

description: MCF7 treated with haloperidol (.00001 M) for 6 h

value: haloperidol


title: EC2004071405AA

description: MCF7 treated with dopamine (.000001 M) for 6 h

value: dopamine


title: EC2004070124AA

description: MCF7 treated with iloprost (.000001 M) for 6 h


title: EC2004070123AA

description: MCF7 treated with pirinixic acid (.0001 M) for 6 h


title: EC2004070121AA

description: MCF7 treated with deferoxamine (.0001 M) for 6 h

value: deferoxamine


title: EC2004071402AA

description: MCF7 with vehicle (DMSO) for 6 h

value: control


title: EC2004070122AA

description: MCF7 treated with calmidazolium (.000005 M) for 6 h

value: calmidazolium


title: EC2004070120AA

description: MCF7 with vehicle (DMSO) for 6 h

value: small molecule


title: EC2004071403AA

description: MCF7 treated with monorden (.0000001 M) for 6 h


title: EC2004070118AA

description: PC3 treated with monorden (.0000001 M) for 6 h


title: EC2004070117AA

description: PC3 treated with imatinib (.00001 M) for 6 h

value: imatinib


title: EC2004112406AA

description: MCF7 treated with probucol (.00001 M) for 6 h

value: probucol


title: EC2004070115AA

description: PC3 treated with pirinixic acid (.0001 M) for 6 h


title: EC2004070105AA

description: PC3 treated with copper sulfate (.0001 M) for 6 h

value: copper sulfate

value: medium


title: CL2004060807AA

value: treatment


title: CL2004060805AA

description: PC3 treated with troglitazone (.00001 M) for 6 h

value: troglitazone


title: CL2004060803AA

description: PC3 with vehicle (DMSO) for 6 h


title: EC2004070116AA

description: PC3 treated with celecoxib (.00001 M) for 6 h

value: celecoxib


title: EC2004070113AA

description: MCF7 treated with quinpirole (.000001 M) for 6 h

value: quinpirole

value: DMSO


title: EC2004070114AA

description: PC3 with vehicle (DMSO) for 6 h

value: 6 h


title: EC2004070102AA

description: PC3 with vehicle (medium) for 6 h


title: CL2004060804AA

description: PC3 treated with LY-294002 (.00001 M) for 6 h


title: EC2004070111AA

description: MCF7 treated with prochlorperazine (.00001 M) for 6 h

value: prochlorperazine


title: EC2004070103AA

description: PC3 treated with tetraethylenepentamine (.0001 M) for 6 h

value: tetraethylenepentamine


title: EC2004070106AA

description: PC3 treated with deferoxamine (.0001 M) for 6 h


title: EC2004070104AA

description: PC3 treated with valproic acid (.001 M) for 6 h

value: valproic acid


title: EC2004070110AA

description: MCF7 treated with cobalt chloride (.0001 M) for 6 h

value: cobalt chloride


title: EC2004060214AA

description: PC3 with vehicle (DMSO) for 6 h

value: control


title: EC2004070108AA

description: MCF7 with vehicle (DMSO) for 6 h


title: CL2004060806AA

description: PC3 treated with rofecoxib (.00001 M) for 6 h

value: rofecoxib


title: EC2004060208AA

description: PC3 with vehicle (DMSO) for 6 h

value: small molecule


title: EC2004060218AA

description: PC3 treated with indometacin (.0001 M) for 6 h

value: indometacin


title: EC2004070109AA

description: MCF7 treated with indometacin (.0001 M) for 6 h


title: EC2004060216AA

description: PC3 treated with 17-allylamino-geldanamycin (.000001 M) for 6 h


title: EC2004060215AA

description: PC3 treated with monorden (.0000001 M) for 6 h

value: monorden


title: EC2004060209AA

description: PC3 treated with diclofenac (.00001 M) for 6 h

value: diclofenac


title: EC2004060212AA

description: PC3 treated with trichostatin A (.0000001 M) for 6 h

value: trichostatin A


title: CL2004060801AA

description: MCF7 with vehicle (ethanol) for 6 h

value: ethanol


title: EC2004060211AA

description: PC3 treated with tretinoin (.000001 M) for 6 h

value: treatment

value: tretinoin


title: EC2004060204AA

description: MCF7 treated with oligomycin (.000001 M) for 6 h

value: oligomycin


title: EC2004060203AA

description: MCF7 treated with arachidonic acid (.00001 M) for 6 h

value: arachidonic acid


title: EC2004052414AA

description: MCF7 with vehicle (medium) for 6 h

value: medium

value: 6 h


title: EC2004052418AA

description: MCF7 treated with W-13 (.00001 M) for 6 h


title: EC2004060210AA

description: PC3 treated with 15-delta prostaglandin J2 (.00001 M) for 6 h

value: 15-delta prostaglandin J2

value: DMSO


title: EC2004052415AA

description: MCF7 treated with novobiocin (.0001 M) for 6 h

value: novobiocin


title: EC2004052411AA

description: PC3 treated with novobiocin (.0001 M) for 6 h


title: EC2004052416AA

description: MCF7 treated with copper sulfate (.0001 M) for 6 h

value: copper sulfate


title: EC2004060205AA


title: EC2004052408AA

description: PC3 with vehicle (medium) for 6 h

value: control


title: EC2004060217AA

description: PC3 treated with TTNPB (.0000001 M) for 6 h

value: small molecule

value: TTNPB


title: EC2004052404AA

description: PC3 treated with rosiglitazone (.00001 M) for 6 h

value: rosiglitazone


title: EC2004052406AA


title: EC2004052405AA

description: PC3 treated with troglitazone (.00001 M) for 6 h

value: troglitazone


title: EC2004052409AA

description: PC3 treated with valproic acid (.001 M) for 6 h

value: valproic acid


title: EC2004052417AA

description: MCF7 treated with oxamic acid (.01 M) for 6 h

value: oxamic acid


title: EC2004052402AA

description: PC3 with vehicle (DMSO) for 6 h


title: EC2004052410AA

description: PC3 treated with sodium phenylbutyrate (.001 M) for 6 h

value: treatment

value: sodium phenylbutyrate


title: EC2004050712AA

description: MCF7 treated with 17-allylamino-geldanamycin (.000001 M) for 6 h


title: EC2004052403AA

description: PC3 treated with LY-294002 (.00001 M) for 6 h


title: EC2004042318AA

description: MCF7 treated with LY-294002 (.0000001 M) for 6 h


title: EC2004050710AA

description: MCF7 treated with chlorpromazine (.000001 M) for 6 h

value: chlorpromazine


title: EC2004050711AA

description: MCF7 treated with iloprost (.000001 M) for 6 h

value: iloprost


title: EC2004042317AA

description: MCF7 treated with staurosporine (.0000001 M) for 6 h

value: staurosporine


title: EC2004042316AA

description: MCF7 treated with thioridazine (.000001 M) for 6 h

value: thioridazine

value: 6 h


title: EC2004042312AA

description: MCF7 treated with chlorpromazine (.00001 M) for 6 h

value: DMSO


title: EC2004042315AA

description: MCF7 treated with trifluoperazine (.00001 M) for 6 h

value: trifluoperazine


title: EC2004050708AA

description: MCF7 with vehicle (DMSO) for 6 h


title: EC2004042310AA

description: MCF7 treated with thioridazine (.00001 M) for 6 h


title: EC2004042308AA

description: MCF7 with vehicle (DMSO) for 6 h


title: EC2004050709AA

description: MCF7 treated with staurosporine (.00000001 M) for 6 h


title: EC2004050703AA

description: ssMCF7 treated with trichostatin A (.0000001 M) for 6 h

value: trichostatin A


title: EC2004050706AA

description: ssMCF7 treated with nordihydroguaiaretic acid (.000001 M) for 6 h

value: nordihydroguaiaretic acid


title: EC2004050704AA

description: ssMCF7 treated with estradiol (.00000001 M) for 6 h

value: small molecule

value: estradiol


title: EC2004041606AA

description: ssMCF7 treated with wortmannin (.00000001 M) for 6 h

value: wortmannin


title: EC2004042309AA

description: MCF7 treated with clozapine (.00001 M) for 6 h

value: clozapine


title: EC2004042302AA

description: HL60 with vehicle (medium) for 6 h

value: control

value: medium


title: EC2004042311AA

description: MCF7 treated with haloperidol (.00001 M) for 6 h

value: treatment

value: haloperidol


title: EC2004042303AA

description: HL60 treated with valproic acid (.001 M) for 6 h

value: valproic acid


title: EC2004042304AA

description: HL60 treated with valproic acid (.01 M) for 6 h


title: EC2004050702AA

description: ssMCF7 with vehicle (DMSO) for 6 h


title: EC2004041608AA

description: MCF7 with vehicle (medium) for 6 h


title: EC2004041612AA

description: MCF7 treated with sodium phenylbutyrate (.001 M) for 6 h

value: sodium phenylbutyrate


title: EC2004042306AA

description: HL60 treated with tetraethylenepentamine (.0001 M) for 6 h

value: tetraethylenepentamine


title: EC2004042305AA

description: HL60 treated with sodium phenylbutyrate (.001 M) for 6 h


title: EC2004041609AA

description: MCF7 treated with tetraethylenepentamine (.00001 M) for 6 h


title: EC2004042314AA

description: MCF7 with vehicle (DMSO) for 6 h


title: EC2004041602AA

description: ssMCF7 with vehicle (DMSO) for 6 h


title: EC2004041605AA

description: ssMCF7 treated with alpha-estradiol (.00000001 M) for 6 h

value: alpha-estradiol


title: EC2004041604AA

description: ssMCF7 treated with sirolimus (.0000001 M) for 6 h

value: sirolimus

value: 6 h


title: 5202764005789148112904.A11

description: MCF7 treated with tyrphostin AG-1478 (.0000316 M) for 6 h

value: tyrphostin AG-1478

value: DMSO


title: EC2004041610AA

description: MCF7 treated with tetraethylenepentamine (.0001 M) for 6 h


title: EC2004041603AA

description: ssMCF7 treated with LY-294002 (.00001 M) for 6 h


title: EC2004032013AA

description: HL60 treated with tretinoin (.000001 M) for 6 h

value: tretinoin


title: 5202764005789148112904.B10

description: MCF7 treated with minocycline (.0000105 M) for 6 h

value: small molecule

value: minocycline


title: EC2004041412AA

description: MCF7 treated with tretinoin (.000001 M) for 6 h


title: EC2004041611AA


title: EC2004032009AA

description: HL60 with vehicle (DMSO) for 6 h


title: EC2004032010AA

description: HL60 treated with estradiol (.00000001 M) for 6 h

value: estradiol


title: EC2004032007AA

description: MCF7 treated with cobalt chloride (.0001 M) for 6 h

value: cobalt chloride


title: EC2004041408AA

description: MCF7 with vehicle (DMSO) for 6 h

value: control


title: 5202764005789148112904.D07

description: MCF7 treated with DL-PPMP (.000002 M) for 6 h

value: DL-PPMP


title: 5202764005789148112904.F11

description: MCF7 treated with tyrphostin AG-825 (.0000252 M) for 6 h

value: treatment

value: tyrphostin AG-825


title: EC2004041409AA

description: MCF7 treated with 17-allylamino-geldanamycin (.000001 M) for 6 h


title: 5202764005789148112904.F10

description: MCF7 treated with doxycycline (.0000144 M) for 6 h

value: doxycycline


title: EC2004060206AA

description: MCF7 treated with clofibrate (.0001 M) for 6 h

value: clofibrate

value: ethanol


title: EC2004032012AA

description: HL60 treated with wortmannin (.00000001 M) for 6 h

value: wortmannin


title: EC2004032011AA

description: HL60 treated with raloxifene (.0000001 M) for 6 h

value: raloxifene


title: 5202764005789148112904.A10

description: MCF7 treated with MG-132 (.000021 M) for 6 h

value: 6 h


title: EC2004041411AA


title: 5202764005789148112904.D08

description: MCF7 treated with cytochalasin B (.0000208 M) for 6 h

value: cytochalasin B


title: EC2004041410AA

description: MCF7 treated with genistein (.00001 M) for 6 h

value: genistein

value: DMSO


title: 5202764005789148112904.E11

description: MCF7 treated with yohimbine (.0000229 M) for 6 h

value: small molecule

value: yohimbine


title: 5202764005789148112904.G12

description: MCF7 treated with 3-hydroxy-DL-kynurenine (.0000092 M) for 6 h


title: EC2004030518AA

description: MCF7 treated with tamoxifen (.000001 M) for 6 h

value: tamoxifen


title: 5202764005789148112904.B07

description: MCF7 treated with BW-B70C (.0000316 M) for 6 h


title: 5202764005789148112904.F12

description: MCF7 treated with phenanthridinone (.0000512 M) for 6 h

value: phenanthridinone


title: 5202764005789148112904.F09

description: MCF7 treated with trichostatin A (.0000001 M) for 6 h

value: trichostatin A


title: EC2004030516AA

description: MCF7 treated with tacrolimus (.000001 M) for 6 h

value: tacrolimus


title: 5202764005789148112904.G11

description: MCF7 treated with 12,13-EODE (.0000002 M) for 6 h

value: treatment


title: EC2004030514AA

description: MCF7 with vehicle (DMSO) for 6 h

value: control


title: EC2004052412AA

description: PC3 treated with fasudil (.00001 M) for 6 h

value: fasudil

value: medium


title: 5202764005789148112904.A08

description: MCF7 treated with phentolamine (.0000115 M) for 6 h

value: phentolamine


title: 5202764005789148112904.G07

description: MCF7 treated with monensin (.0000109 M) for 6 h

value: monensin


title: EC2004030515AA

description: MCF7 treated with celecoxib (.00001 M) for 6 h

value: celecoxib


title: EC2004030512AA

description: ssMCF7 treated with raloxifene (.0000001 M) for 6 h

value: raloxifene

value: 6 h


title: EC2004030511AA

description: ssMCF7 treated with tamoxifen (.000001 M) for 6 h


title: 5202764005789148112904.A12

description: MCF7 with vehicle (DMSO) for 6 h


title: 5202764005789148112904.H10

description: MCF7 treated with demecolcine (.0000117 M) for 6 h

value: demecolcine


title: EC2004030510AA

description: ssMCF7 treated with dexamethasone (.000001 M) for 6 h

value: dexamethasone

value: DMSO


title: 5202764005789148112904.B11

description: MCF7 with vehicle (DMSO) for 6 h

value: small molecule


title: EC2004030508AA

description: ssMCF7 with vehicle (DMSO) for 6 h


title: EC2004041405AA

description: MCF7 treated with fulvestrant (.000001 M) for 6 h

value: fulvestrant


title: 5202764005789148112904.E09

description: MCF7 with vehicle (DMSO) for 6 h


title: 5202764005789148112904.A04

description: MCF7 treated with wortmannin (.00000001 M) for 6 h

value: wortmannin


title: 5202764005789148112904.G08

description: MCF7 with vehicle (DMSO) for 6 h


title: EC2004032005AA

description: HL60 treated with rofecoxib (.00001 M) for 6 h

value: rofecoxib


title: EC2004030509AA

description: ssMCF7 treated with estradiol (.00000001 M) for 6 h

value: estradiol


title: 5202764005789148112904.H08

description: MCF7 treated with (-)-catechin (.000011 M) for 6 h

value: treatment

value: (-)-catechin


title: 5202764005789148112904.D10

description: MCF7 with vehicle (DMSO) for 6 h

value: control


title: EC2004041404AA

description: MCF7 treated with imatinib (.00001 M) for 6 h

value: imatinib


title: 5202764005789148112904.A02

description: MCF7 treated with estradiol (.00000001 M) for 6 h


title: EC2004041406AA

description: MCF7 treated with pirinixic acid (.0001 M) for 6 h

value: pirinixic acid


title: 5202764005789148112904.A05

description: MCF7 treated with haloperidol (.00001 M) for 6 h

value: haloperidol


title: EC2004032004AA

description: HL60 treated with troglitazone (.00001 M) for 6 h

value: troglitazone


title: EC2004032003AA

description: HL60 treated with rosiglitazone (.00001 M) for 6 h

value: rosiglitazone


title: 5202764005789148112904.A03

description: MCF7 treated with sirolimus (.0000001 M) for 6 h

value: sirolimus

value: 6 h


title: 5202764005789148112904.H07

description: MCF7 with vehicle (DMSO) for 6 h


title: EC2004032002AA

description: HL60 with vehicle (DMSO) for 6 h


title: 5202764005789148112904.A01

description: MCF7 treated with valproic acid (.0005 M) for 6 h

value: valproic acid


title: 5202764005789148112904.B04

description: MCF7 treated with fulvestrant (.00000001 M) for 6 h

value: DMSO


title: 5202764005789148112904.B06

description: MCF7 treated with LY-294002 (.00001 M) for 6 h

value: small molecule


title: 5202764005789148112904.B03

description: MCF7 treated with fluphenazine (.00001 M) for 6 h

value: fluphenazine


title: 5202764005789148112904.B02


title: EC2004030502AA

description: HL60 with vehicle (DMSO) for 6 h


title: EC2004041403AA

description: MCF7 treated with estradiol (.0000001 M) for 6 h


title: EC2004041402AA

description: MCF7 with vehicle (DMSO) for 6 h


title: EC2004021312AA

description: MCF7 treated with valproic acid (.00005 M) for 6 h

value: medium


title: EC2004030503AA

description: HL60 treated with LY-294002 (.00001 M) for 6 h


title: EC2004030504AA

description: HL60 treated with sirolimus (.0000001 M) for 6 h


title: 5202764005789148112904.C03

description: MCF7 treated with 15-delta prostaglandin J2 (.00001 M) for 6 h

value: 15-delta prostaglandin J2


title: 5202764005789148112904.B01

description: MCF7 treated with genistein (.00001 M) for 6 h

value: genistein


title: EC2004030506AA

description: HL60 treated with trichostatin A (.0000001 M) for 6 h

value: treatment

value: trichostatin A


title: 5202764005789148112904.C05

description: MCF7 treated with rosiglitazone (.00001 M) for 6 h


title: EC2004021306AA

description: MCF7 treated with 2-deoxy-D-glucose (.01 M) for 6 h


title: 5202764005789148112904.D02

description: MCF7 treated with 17-allylamino-geldanamycin (.000001 M) for 6 h


title: EC2004021310AA

description: MCF7 treated with valproic acid (.002 M) for 6 h


title: 5202764005789148112904.D03


title: EC2004021305AA

description: MCF7 treated with fasudil (.00001 M) for 6 h

value: fasudil


title: 5202764005789148112904.D06

description: MCF7 treated with geldanamycin (.000001 M) for 6 h

value: geldanamycin


title: EC2004021309AA

description: MCF7 treated with valproic acid (.01 M) for 6 h


title: EC2004021308AA

description: MCF7 with vehicle (medium) for 6 h

value: control


title: EC2004021304AA

description: MCF7 treated with novobiocin (.0001 M) for 6 h

value: novobiocin


title: 5202764005789148112904.C02

description: MCF7 treated with thioridazine (.00001 M) for 6 h

value: thioridazine


title: EC2004021311AA

description: MCF7 treated with valproic acid (.0005 M) for 6 h


title: EC2004021302AA

description: MCF7 with vehicle (medium) for 6 h


title: 5202764005789148112904.C06

description: MCF7 treated with trichostatin A (.000001 M) for 6 h


title: 5202764005789148112904.D05

description: MCF7 treated with LY-294002 (.00001 M) for 6 h


title: 5202764005789148112904.E06

description: MCF7 treated with nordihydroguaiaretic acid (.000001 M) for 6 h

value: nordihydroguaiaretic acid


title: 5202764005789148112904.E05

description: MCF7 treated with valproic acid (.00005 M) for 6 h


title: EC2004021303AA

description: MCF7 treated with sodium phenylbutyrate (.0001 M) for 6 h

value: sodium phenylbutyrate


title: 5202764005789148112904.E02

description: MCF7 treated with vorinostat (.00001 M) for 6 h

value: vorinostat

value: 6 h


title: 5202764005789148112904.E04

description: MCF7 treated with sirolimus (.0000001 M) for 6 h

value: sirolimus

value: DMSO


title: EC2004010605AA

description: MCF7 treated with felodipine (.00001 M) for 6 h

value: small molecule

value: felodipine


title: 5202764005789148112904.F05

description: MCF7 treated with chlorpromazine (.000001 M) for 6 h

value: chlorpromazine


title: EC2004012212AA

description: MCF7 treated with mercaptopurine (.0001 M) for 6 h

value: mercaptopurine


title: 5202764005789148112904.E01

description: MCF7 treated with monorden (.0000001 M) for 6 h

value: treatment

value: monorden


title: 5202764005789148112904.F06

description: MCF7 treated with 17-allylamino-geldanamycin (.000001 M) for 6 h


title: EC2004010604AA

description: MCF7 treated with nitrendipine (.00001 M) for 6 h

value: nitrendipine


title: EC2004010603AA

description: MCF7 treated with nifedipine (.00001 M) for 6 h

value: nifedipine


title: EC2004010606AA

description: MCF7 treated with azathioprine (.0001 M) for 6 h

value: azathioprine


title: EC2004012208AA

description: MCF7 with vehicle (DMSO) for 6 h

value: control


title: EC2004012211AA

description: MCF7 treated with diclofenac (.00001 M) for 6 h

value: diclofenac


title: EC2004012210AA

description: MCF7 treated with trichostatin A (.0000001 M) for 6 h

value: trichostatin A


title: 5202764005789148112904.F03

description: MCF7 treated with prochlorperazine (.00001 M) for 6 h

value: prochlorperazine


title: EC2004012209AA


title: 5202764005789148112904.G03

description: MCF7 treated with valproic acid (.001 M) for 6 h

value: valproic acid


title: 5202764005789148112904.F04

description: MCF7 treated with LY-294002 (.0000001 M) for 6 h

value: 6 h


title: 5202764005789148112904.F01

description: MCF7 treated with 17-dimethylamino-geldanamycin (.0000001 M) for 6 h


title: 5202764005789148112904.G06


title: 5202764005789148112904.G04

description: MCF7 treated with alpha-estradiol (.00000001 M) for 6 h

value: alpha-estradiol


title: EC2004012205AA

description: MCF7 treated with arachidonyltrifluoromethane (.00001 M) for 6 h

value: arachidonyltrifluoromethane

value: DMSO


title: EC2004012206AA

description: MCF7 treated with LY-294002 (.00001 M) for 6 h

value: small molecule


title: 5202764005789148112904.G05

description: MCF7 treated with tretinoin (.000001 M) for 6 h

value: tretinoin


title: EC2004021313AA

description: MCF7 with vehicle (DMSO) for 6 h


title: 5202764005789148112904.H06

description: MCF7 treated with sirolimus (.0000001 M) for 6 h

value: sirolimus


title: 5202764005789148112904.H05

value: treatment


title: 5202764005789148112904.A06

description: MCF7 with vehicle (DMSO) for 6 h


title: 5202764005789148112904.H04

description: MCF7 treated with fulvestrant (.000001 M) for 6 h

value: fulvestrant


title: 5202764005789148112904.B05

description: MCF7 with vehicle (DMSO) for 6 h


title: EC2004011605AA

description: MCF7 treated with N-phenylanthranilic acid (.00001 M) for 6 h

value: N-phenylanthranilic acid


title: EC2004011604AA

description: MCF7 treated with flufenamic acid (.00001 M) for 6 h

value: flufenamic acid


title: 5202764005789148112904.D04

description: MCF7 with vehicle (DMSO) for 6 h


title: EC2004011606AA


title: 5202764005789148112904.H03

description: MCF7 treated with acetylsalicylic acid (.0001 M) for 6 h

value: acetylsalicylic acid


title: 5202764005789148112904.E03

description: MCF7 with vehicle (DMSO) for 6 h

value: control


title: EC2003122318AA

description: MCF7 treated with exisulind (.00005 M) for 6 h

value: exisulind


title: EC2004012203AA

description: MCF7 treated with monorden (.0000001 M) for 6 h

value: monorden


title: 5202764005789148112904.H01

description: MCF7 with vehicle (DMSO) for 6 h


title: EC2004011602AA

description: MCF7 with vehicle (DMSO) for 6 h


title: 5202764005789148112904.G02

description: MCF7 with vehicle (DMSO) for 6 h


title: EC2004011603AA


title: 5202764005791175120104.A10

description: MCF7 treated with wortmannin (.00000001 M) for 6 h

value: wortmannin


title: EC2004010817AA

description: MCF7 treated with staurosporine (.000001 M) for 6 h

value: staurosporine


title: EC2003122317AA

description: MCF7 treated with NU-1025 (.0001 M) for 6 h

value: 6 h


title: 5202764005791175120104.A09


title: EC2003122314AA

description: MCF7 with vehicle (DMSO) for 6 h


title: EC2003122315AA

description: MCF7 treated with monastrol (.0001 M) for 6 h

value: monastrol


title: EC2003122311AA


title: EC2003122308AA

description: MCF7 with vehicle (DMSO) for 6 h


title: EC2003122310AA

description: MCF7 treated with sulindac sulfide (.00005 M) for 6 h

value: sulindac sulfide


title: 5202764005791175120104.B12

value: DMSO


title: 5202764005791175120104.A11

description: MCF7 treated with haloperidol (.00001 M) for 6 h

value: small molecule

value: haloperidol


title: EC2003122309AA

description: MCF7 treated with sulindac (.00005 M) for 6 h

value: sulindac


title: EC2003122312AA

description: MCF7 treated with fulvestrant (.00000001 M) for 6 h

value: treatment


title: EC2004010602AA

description: MCF7 with vehicle (DMSO) for 6 h


title: 5202764005791175120104.B07

description: MCF7 treated with genistein (.00001 M) for 6 h

value: genistein


title: 5202764005791175120104.C12

description: MCF7 treated with trichostatin A (.000001 M) for 6 h

value: trichostatin A


title: 5202764005791175120104.A08

description: MCF7 treated with estradiol (.00000001 M) for 6 h

value: estradiol


title: 5202764005791175120104.B08

description: MCF7 treated with LY-294002 (.00001 M) for 6 h


title: 5202764005789148112904.C04

description: MCF7 treated with troglitazone (.00001 M) for 6 h

value: troglitazone


title: 5202764005789148112904.H02


title: 5202764005791175120104.A07

description: MCF7 treated with valproic acid (.0005 M) for 6 h

value: valproic acid


title: EC2003122306AA

description: MCF7 treated with tacrolimus (.000001 M) for 6 h

value: tacrolimus


title: 5202764005791175120104.B09

description: MCF7 treated with fluphenazine (.00001 M) for 6 h

value: fluphenazine


title: 5202764005791175120104.C11

description: MCF7 treated with rosiglitazone (.00001 M) for 6 h

value: rosiglitazone


title: EC2003122302AA

description: MCF7 with vehicle (DMSO) for 6 h

value: control


title: EC2003122304AA

description: MCF7 treated with fludrocortisone (.000001 M) for 6 h

value: fludrocortisone

value: 6 h


title: EC2003122305AA

description: MCF7 treated with quercetin (.000001 M) for 6 h

value: quercetin


title: 5202764005791175120104.C10

value: DMSO


title: EC2003122303AA

value: small molecule


title: EC2004010812AA

description: MCF7 treated with genistein (.000001 M) for 6 h


title: 5202764005791175120104.C07

description: MCF7 treated with clozapine (.00001 M) for 6 h

value: clozapine


title: EC2004012204AA

description: MCF7 treated with sirolimus (.0000001 M) for 6 h

value: sirolimus


title: EC2004030505AA

description: HL60 treated with sodium phenylbutyrate (.0001 M) for 6 h

value: treatment

value: sodium phenylbutyrate


title: EC2004010809AA

description: MCF7 treated with prednisolone (.000001 M) for 6 h

value: prednisolone


title: EC2004010811AA

value: genistein


title: EC2004010805AA

description: MCF7 treated with clofibrate (.00015 M) for 6 h

value: clofibrate

value: ethanol


title: EC2003121204AA

description: MCF7 treated with rofecoxib (.00001 M) for 6 h

value: rofecoxib


title: 5202764005791175120104.C08

description: MCF7 treated with thioridazine (.00001 M) for 6 h

value: thioridazine


title: EC2004010808AA

description: MCF7 with vehicle (DMSO) for 6 h


title: EC2003121203AA

description: MCF7 treated with dexamethasone (.000001 M) for 6 h

value: dexamethasone


title: EC2004010804AA

description: MCF7 treated with indometacin (.00002 M) for 6 h

value: indometacin


title: EC2003121206AA

description: MCF7 treated with LY-294002 (.00001 M) for 6 h


title: EC2004010810AA

description: MCF7 treated with thalidomide (.0001 M) for 6 h

value: thalidomide


title: EC2003121106AA

description: MCF7 treated with SC-58125 (.00001 M) for 6 h

value: 6 h


title: 5202764005791175120104.E07

description: MCF7 treated with monorden (.0000001 M) for 6 h

value: monorden


title: 5202764005791175120104.D11

value: DMSO


title: EC2004010806AA

description: MCF7 treated with MK-886 (.000001 M) for 6 h

value: small molecule


title: 5202764005791175120104.D09

description: MCF7 treated with 17-allylamino-geldanamycin (.000001 M) for 6 h


title: EC2003121202AA

description: MCF7 with vehicle (DMSO) for 6 h

value: control


title: EC2004010803AA

description: MCF7 treated with ciclosporin (.000001 M) for 6 h

value: ciclosporin


title: 5202764005791175120104.D12

description: MCF7 treated with geldanamycin (.000001 M) for 6 h

value: treatment

value: geldanamycin


title: 5202764005791175120104.D08


title: 5202764005791175120104.E08

description: MCF7 treated with vorinostat (.00001 M) for 6 h

value: vorinostat


title: 5202764005791175120104.D07

description: MCF7 treated with trifluoperazine (.00001 M) for 6 h

value: trifluoperazine


title: 5202764005791175120104.E10

description: MCF7 treated with sirolimus (.0000001 M) for 6 h

value: sirolimus


title: EC2004010802AA

description: MCF7 with vehicle (ethanol) for 6 h

value: ethanol


title: 5202764005791175120104.F11

description: MCF7 treated with chlorpromazine (.000001 M) for 6 h

value: chlorpromazine


title: 5202764005791175120104.E12

description: MCF7 treated with nordihydroguaiaretic acid (.000001 M) for 6 h

value: nordihydroguaiaretic acid


title: 5202764005791175120104.F12


title: 5202764005791175120104.F10

description: MCF7 treated with LY-294002 (.0000001 M) for 6 h


title: 5202764005791175120104.C09

description: MCF7 treated with 15-delta prostaglandin J2 (.00001 M) for 6 h

value: 15-delta prostaglandin J2


title: EC2003120405AA

description: MCF7 treated with TTNPB (.0000001 M) for 6 h

value: TTNPB


title: EC2003121105AA

description: MCF7 treated with LM-1685 (.00001 M) for 6 h


title: 5202764005791175120104.G07

description: MCF7 treated with estradiol (.0000001 M) for 6 h

value: estradiol


title: EC2003110405AA

value: 6 h


title: EC2003121102AA

description: MCF7 with vehicle (DMSO) for 6 h


title: 5202764005791175120104.G09

description: MCF7 treated with valproic acid (.001 M) for 6 h

value: valproic acid


title: EC2003110406AA

description: MCF7 treated with SC-58125 (.00001 M) for 6 h

value: DMSO


title: 5202764005791175120104.A12

description: MCF7 with vehicle (DMSO) for 6 h

value: small molecule


title: EC2003121103AA

description: MCF7 treated with rofecoxib (.00001 M) for 6 h

value: rofecoxib


title: EC2003120402AA

description: MCF7 with vehicle (DMSO) for 6 h

value: control


title: EC2003121104AA

description: MCF7 treated with celecoxib (.00001 M) for 6 h

value: treatment

value: celecoxib


title: 5202764005791175120104.F07

description: MCF7 treated with 17-dimethylamino-geldanamycin (.0000001 M) for 6 h


title: 5202764005791175120104.H10

description: MCF7 treated with fulvestrant (.000001 M) for 6 h

value: fulvestrant


title: 5202764005791175120104.G10

description: MCF7 treated with alpha-estradiol (.00000001 M) for 6 h

value: alpha-estradiol


title: 5202764005791175120104.B11

description: MCF7 with vehicle (DMSO) for 6 h


title: 5202764005791175120104.D10

description: MCF7 with vehicle (DMSO) for 6 h


title: EC2003120403AA

description: MCF7 treated with 17-allylamino-geldanamycin (.0000001 M) for 6 h


title: 5202764005791175120104.G11

description: MCF7 treated with tretinoin (.000001 M) for 6 h

value: tretinoin


title: EC2003120404AA

description: MCF7 treated with tomelukast (.000001 M) for 6 h

value: tomelukast


title: 5202764005791175120104.E09

description: MCF7 with vehicle (DMSO) for 6 h


title: 5202764005791175120104.H09

description: MCF7 treated with acetylsalicylic acid (.0001 M) for 6 h

value: acetylsalicylic acid


title: EC2003103002AA

description: MCF7 with vehicle (DMSO) for 6 h


title: 5202764005791175120104.H07

description: MCF7 with vehicle (DMSO) for 6 h


title: EC2003110403AA


title: EC2003103003AA


title: EC2003103004AA

description: MCF7 treated with raloxifene (.0000001 M) for 6 h

value: raloxifene


title: 5202764005791175120104.G12

description: MCF7 treated with trichostatin A (.0000001 M) for 6 h

value: trichostatin A


title: 5202764005791175120104.H08

description: MCF7 treated with haloperidol (.00001 M) for 6 h

value: haloperidol


title: EC2003100205AA

description: MCF7 treated with sulindac (.0001 M) for 6 h

value: sulindac


title: 5202764005791175120104.A04

description: MCF7 treated with trichostatin A (.000001 M) for 6 h

value: 6 h


title: 5202764005791175120104.A02

description: MCF7 treated with ionomycin (.000002 M) for 6 h

value: ionomycin


title: EC2003100202AA

description: MCF7 with vehicle (DMSO) for 6 h

value: DMSO


title: 5202764005791175120104.A05

description: MCF7 treated with depudecin (.000001 M) for 6 h

value: small molecule

value: depudecin


title: EC2003100106AA

value: rofecoxib


title: EC2003100203AA

description: MCF7 treated with amitriptyline (.000001 M) for 6 h

value: treatment

value: amitriptyline


title: 5202764005791175120104.A01

description: MCF7 treated with pyrvinium (.00000125 M) for 6 h

value: pyrvinium


title: EC2003100105AA

description: MCF7 treated with exemestane (.00000001 M) for 6 h

value: exemestane


title: EC2003110402AA

description: MCF7 with vehicle (DMSO) for 6 h

value: control


title: 5202764005791175120104.C06

description: MCF7 treated with geldanamycin (.000001 M) for 6 h

value: geldanamycin


title: EC2003120406AA

value: tretinoin


title: EC2003100104AA

description: MCF7 treated with dexverapamil (.00001 M) for 6 h

value: dexverapamil


title: 5202764005791175120104.E11

description: MCF7 treated with valproic acid (.00005 M) for 6 h

value: valproic acid


title: EC2003110404AA

description: MCF7 treated with celecoxib (.00001 M) for 6 h

value: celecoxib


title: 5202764005791175120104.B02

description: MCF7 treated with ikarugamycin (.000002 M) for 6 h

value: ikarugamycin


title: EC2003103006AA

description: MCF7 treated with sulfasalazine (.0001 M) for 6 h

value: sulfasalazine

value: 6 h


title: EC2003100102AA

description: MCF7 with vehicle (DMSO) for 6 h

value: DMSO


title: 5202764005791175120104.C04

description: MCF7 treated with 5230742 (.000017 M) for 6 h

value: small molecule


title: 5202764005791175120104.C05

description: MCF7 treated with oxaprozin (.0003 M) for 6 h

value: oxaprozin


title: EC2003092505AA

description: MCF7 treated with tamoxifen (.000001 M) for 6 h

value: tamoxifen


title: EC2003100103AA

description: MCF7 treated with verapamil (.00001 M) for 6 h

value: treatment

value: verapamil


title: 5202764005791175120104.F08

description: MCF7 treated with valproic acid (.0002 M) for 6 h


title: 5202764005791175120104.H11

description: MCF7 treated with 17-allylamino-geldanamycin (.000001 M) for 6 h


title: 5202764005791175120104.B04

description: MCF7 treated with 5182598 (.000025 M) for 6 h


title: 5202764005791175120104.F09

description: MCF7 treated with prochlorperazine (.00001 M) for 6 h

value: prochlorperazine


title: EC2003100206AA

description: MCF7 treated with tacrolimus (.000001 M) for 6 h

value: tacrolimus


title: EC2003092506AA

description: MCF7 treated with chlorpropamide (.0001 M) for 6 h

value: chlorpropamide


title: 5202764005791175120104.G08

description: MCF7 with vehicle (DMSO) for 6 h

value: control


title: 5202764005791175120104.D06

description: MCF7 treated with tretinoin (.000001 M) for 6 h

value: tretinoin


title: 5202764005791175120104.H12

description: MCF7 treated with sirolimus (.0000001 M) for 6 h

value: sirolimus


title: 5202764005791175120104.B06

description: MCF7 treated with wortmannin (.000001 M) for 6 h

value: wortmannin


title: 5202764005791175120104.D05

description: MCF7 treated with felodipine (.00001 M) for 6 h

value: felodipine


title: EC2003103005AA

description: MCF7 treated with nordihydroguaiaretic acid (.000001 M) for 6 h

value: nordihydroguaiaretic acid


title: EC2003092504AA

description: MCF7 treated with tolbutamide (.0001 M) for 6 h

value: tolbutamide


title: EC2003092306AA

description: MCF7 treated with mesalazine (.0001 M) for 6 h

value: mesalazine

value: 6 h


title: 5202764005791175120104.E04

description: MCF7 treated with bucladesine (.000002 M) for 6 h

value: small molecule

value: bucladesine

value: DMSO


title: EC2003092304AA

description: MCF7 treated with alpha-estradiol (.00000001 M) for 6 h

value: treatment

value: alpha-estradiol


title: 5202764005791175120104.E02

description: MCF7 treated with resveratrol (.00001 M) for 6 h

value: resveratrol


title: 5202764005791175120104.E05

description: MCF7 treated with 5279552 (.000022 M) for 6 h


title: 5202764005791175120104.F06

description: MCF7 treated with 5224221 (.000012 M) for 6 h


title: EC2003092303AA

description: MCF7 treated with estradiol (.00000001 M) for 6 h

value: estradiol


title: 5202764005791175120104.F05

description: MCF7 treated with 5248896 (.000011 M) for 6 h


title: 5202764005791175120104.E06

description: MCF7 treated with 5253409 (.000017 M) for 6 h


title: EC2003092305AA

description: MCF7 treated with dexamethasone (.000001 M) for 6 h

value: dexamethasone


title: EC2003092502AA

description: MCF7 with vehicle (DMSO) for 6 h

value: control


title: EC2003092302AA

description: MCF7 with vehicle (DMSO) for 6 h


title: 5202764005791175120104.G05

description: MCF7 treated with 5255229 (.000013 M) for 6 h


title: 5202764005791175120104.F02

description: MCF7 treated with carbamazepine (.0000001 M) for 6 h

value: carbamazepine


title: 5202764005791175120104.G06

description: MCF7 treated with 5211181 (.000012 M) for 6 h


title: 5202764005791175120104.G03

description: MCF7 treated with 17-allylamino-geldanamycin (.000001 M) for 6 h


title: 5202764005791175120104.F04

description: MCF7 treated with blebbistatin (.000017 M) for 6 h

value: blebbistatin


title: 5202764005791175120104.G04

description: MCF7 treated with Y-27632 (.000003 M) for 6 h


title: 5202764005791175120104.H05

description: MCF7 treated with 5252917 (.000014 M) for 6 h


title: 5202764005791175120104.F03

description: MCF7 treated with monorden (.0000001 M) for 6 h

value: monorden


title: EC2003090506AA

description: MCF7 treated with metformin (.001 M) for 6 h

value: metformin

value: medium


title: EC2003091105AA

description: MCF7 treated with phenyl biguanide (.00001 M) for 6 h

value: phenyl biguanide


title: 5202764005791175120104.H03

description: MCF7 treated with prazosin (.00001 M) for 6 h

value: prazosin


title: EC2003091106AA

description: MCF7 treated with valproic acid (.001 M) for 6 h

value: valproic acid

value: 6 h


title: 5202764005791175120104.A06

description: MCF7 with vehicle (DMSO) for 6 h

value: small molecule


title: EC2003090504AA

description: MCF7 treated with metformin (.00001 M) for 6 h


title: EC2003091104AA

description: MCF7 treated with phenformin (.00001 M) for 6 h

value: phenformin


title: EC2003090502AA

description: MCF7 with vehicle (medium) for 6 h


title: EC2003091103AA

value: treatment


title: EC2003090505AA

description: MCF7 treated with metformin (.0000001 M) for 6 h


title: EC2003090503AA


title: 5202764005791175120104.D04

description: MCF7 with vehicle (DMSO) for 6 h

value: DMSO


title: 5202764005790181113004.A10

description: MCF7 treated with sirolimus (.0000001 M) for 6 h

value: sirolimus


title: 5202764005791175120104.B05

description: MCF7 with vehicle (DMSO) for 6 h


title: 5202764005791175120104.G02

description: MCF7 with vehicle (DMSO) for 6 h


title: 5202764005790181113004.A09

description: MCF7 treated with decitabine (.0000001 M) for 6 h

value: decitabine


title: 5202764005790181113004.A08


title: 5202764005790181113004.A07

description: MCF7 treated with ikarugamycin (.000002 M) for 6 h

value: ikarugamycin


title: 5202764005791175120104.H01

description: MCF7 with vehicle (DMSO) for 6 h

value: control


title: 5202764005790181113004.A11

description: MCF7 treated with celecoxib (.00001 M) for 6 h

value: celecoxib


title: 5202764005790181113004.B10


title: 5202764005791175120104.E03

description: MCF7 with vehicle (DMSO) for 6 h


title: 5202764005790181113004.B12

description: MCF7 treated with quercetin (.000001 M) for 6 h

value: quercetin


title: 5202764005790181113004.B07

description: MCF7 treated with colforsin (.00005 M) for 6 h

value: colforsin


title: 5202764005791175120104.H02

description: MCF7 treated with rottlerin (.00001 M) for 6 h

value: rottlerin


title: 5202764005790181113004.C08

description: MCF7 treated with 5140203 (.000015 M) for 6 h


title: 5202764005790181113004.E08

description: MCF7 treated with 5213008 (.000018 M) for 6 h


title: 5202764005790181113004.F12

description: MCF7 treated with 5152487 (.00001 M) for 6 h


title: 5202764005790181113004.B09

description: MCF7 treated with topiramate (.000003 M) for 6 h

value: topiramate


title: 5202764005790181113004.C10

description: MCF7 treated with trifluoperazine (.00001 M) for 6 h

value: trifluoperazine


title: 5202764005790181113004.A12

description: MCF7 with vehicle (DMSO) for 6 h


title: 5202764005790181113004.G09

description: MCF7 treated with celastrol (.0000025 M) for 6 h

value: celastrol


title: 5202764005790181113004.D09

description: MCF7 treated with 5109870 (.000025 M) for 6 h


title: 5202764005790181113004.E12

description: MCF7 treated with 5114445 (.00001 M) for 6 h


title: 5202764005790181113004.E11

description: MCF7 treated with 5186324 (.000002 M) for 6 h


title: 5202764005790181113004.G11

description: MCF7 treated with 5286656 (.00005 M) for 6 h


title: 5202764005790181113004.C09

description: MCF7 treated with HC toxin (.0000001 M) for 6 h

value: HC toxin


title: 5202764005790181113004.B08

value: 6 h


title: 5202764005790181113004.D11

description: MCF7 treated with clotrimazole (.00005 M) for 6 h

value: small molecule

value: clotrimazole


title: 5202764005790181113004.F08

description: MCF7 treated with 5162773 (.000007 M) for 6 h

value: treatment


title: 5202764005790181113004.D12

description: MCF7 treated with calmidazolium (.000005 M) for 6 h

value: calmidazolium

value: DMSO


title: 5202764005790181113004.H09

description: MCF7 treated with ionomycin (.000002 M) for 6 h

value: ionomycin


title: 5202764005790181113004.E09

description: MCF7 with vehicle (DMSO) for 6 h


title: 5202764005790181113004.D10

description: MCF7 with vehicle (DMSO) for 6 h


title: 5202764005790181113004.G08

description: MCF7 with vehicle (DMSO) for 6 h


title: 5202764005790181113004.D08

description: MCF7 treated with 5151277 (.000014 M) for 6 h


title: 5202764005790181113004.H07

description: MCF7 with vehicle (DMSO) for 6 h


title: 5202764005790181113004.C11

description: MCF7 treated with wortmannin (.00000001 M) for 6 h

value: wortmannin


title: 5202764005790181113004.B11

description: MCF7 with vehicle (DMSO) for 6 h

value: control


title: 5202764005790181113004.A04

description: MCF7 treated with trichostatin A (.000001 M) for 6 h

value: trichostatin A


title: 5202764005790181113004.F09

description: MCF7 treated with pararosaniline (.00001 M) for 6 h

value: pararosaniline


title: 5202764005790181113004.G12

description: MCF7 treated with 5149715 (.00001 M) for 6 h


title: 5202764005790181113004.A01

description: MCF7 treated with pyrvinium (.00000125 M) for 6 h

value: pyrvinium


title: 5202764005790181113004.A05

description: MCF7 treated with depudecin (.000001 M) for 6 h

value: depudecin


title: 5202764005790181113004.H12

description: MCF7 treated with 5186223 (.000012 M) for 6 h


title: 5202764005790181113004.D06

description: MCF7 treated with tretinoin (.000001 M) for 6 h

value: tretinoin


title: 5202764005790181113004.E05

description: MCF7 treated with 5279552 (.000022 M) for 6 h


title: 5202764005790181113004.E04

description: MCF7 treated with bucladesine (.000002 M) for 6 h

value: bucladesine


title: 5202764005790181113004.A02


title: 5202764005790181113004.E06

description: MCF7 treated with 5253409 (.000017 M) for 6 h


title: 5202764005790181113004.B06

description: MCF7 treated with wortmannin (.000001 M) for 6 h


title: 5202764005790181113004.C06

description: MCF7 treated with geldanamycin (.000001 M) for 6 h

value: geldanamycin


title: 5202764005790181113004.F05

description: MCF7 treated with 5248896 (.000011 M) for 6 h


title: EC2003092503AA

description: MCF7 treated with chlorpropamide (.0001 M) for 6 h

value: chlorpropamide


title: 5202764005790181113004.B02

description: MCF7 treated with ikarugamycin (.000002 M) for 6 h

value: ikarugamycin

value: 6 h


title: 5202764005790181113004.F06

description: MCF7 treated with 5224221 (.000012 M) for 6 h

value: small molecule


title: 5202764005790181113004.F02

description: MCF7 treated with carbamazepine (.0000001 M) for 6 h

value: treatment

value: carbamazepine


title: 5202764005790181113004.D05

description: MCF7 treated with felodipine (.00001 M) for 6 h

value: felodipine

value: DMSO


title: 5202764005790181113004.C05

description: MCF7 treated with oxaprozin (.0003 M) for 6 h

value: oxaprozin


title: EC2003091102AA

description: MCF7 with vehicle (medium) for 6 h

value: control

value: medium


title: 5202764005790181113004.E02

description: MCF7 treated with resveratrol (.00001 M) for 6 h

value: resveratrol


title: 5202764005790181113004.G05

description: MCF7 treated with 5255229 (.000013 M) for 6 h


title: 5202764005790181113004.H08

description: MCF7 treated with docosahexaenoic acid ethyl ester (.0001 M) for 6 h

value: docosahexaenoic acid ethyl ester


title: 5202764005790181113004.F03

description: MCF7 treated with monorden (.0000001 M) for 6 h

value: monorden


title: 5202764005790181113004.B04

description: MCF7 treated with 5182598 (.000025 M) for 6 h


title: 5202764005790181113004.G06

description: MCF7 treated with 5211181 (.000012 M) for 6 h


title: 5202764005790181113004.H05

description: MCF7 treated with 5252917 (.000014 M) for 6 h


title: 5202764005790181113004.F04

description: MCF7 treated with blebbistatin (.000017 M) for 6 h

value: blebbistatin


title: 5202764005790181113004.G03

description: MCF7 treated with 17-allylamino-geldanamycin (.000001 M) for 6 h


title: 5202764005790181113004.A06

description: MCF7 with vehicle (DMSO) for 6 h


title: 5202764005790181113004.C04

description: MCF7 treated with 5230742 (.000017 M) for 6 h


title: 5202764005790181113004.G04

description: MCF7 treated with Y-27632 (.000003 M) for 6 h


title: 5202764005790181113004.B05

description: MCF7 with vehicle (DMSO) for 6 h


title: 5202764005790181113004.H03

description: MCF7 treated with prazosin (.00001 M) for 6 h

value: prazosin


title: 5202764005790181113004.D04

description: MCF7 with vehicle (DMSO) for 6 h


title: PPL

city: Cork

first: John

middle: Andrew

last: Mac Sharry

state: Cork

address: College Road

department: APC, Biosciences Instiute

country: Ireland

institute: UCC

description: Phoretix Array2 Software (Nonlinear Dynamics, Newcastle-upon-Tyne, UK) was used to analyze the array images.  The images were background subtracted and the intensity normalized to negative controls and to the selected housekeeping gene, beta-actin.  The normalized data was then imported to Microsoft Excel (Microsoft, Ireland), where the ratios of differences between the samples of interest were calculated.  The normalized data was also analyzed using Cluster and TreeView (Michael Eisen, Stanford University, USA).  Using Cluster, the array data was filtered; log transformed, median centered and hierarchically clustered and visualized using TreeView.  The Cluster transformed data was also analyzed using J-Express software (MolMine AS, Bergen, Norway) to evaluate common gene expression trends.  Gene lists were complied and the function of the genes of interest were determined using Genecards (http://bioinformatics.weizmann.ac.il/cards-bin/carddisp?[gene) and the PubMed database (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed).

hyb_protocol: The 33P cDNA probes from the samples of interest were hybridized overnight at 65C to the Mouse Cytokine Expression Array Version 1.0 (Sigma-R&D Systems).  The cDNA arrays were then washed three times with 0.5X SSPE/1%SDS (low stringency) and twice at 65C with 0.1 X SSPE/1%SDS (high stringency). The arrays were then exposed to a phosphorimaging screen (Molecular Dynamics, Amersham Biosciences, UK) overnight.  The screens were then scanned at 50-m pixel size using a STORM phosphorimager (Molecular Dynamics).

source_name: Purified Peyer's patch lymphocytes

label_protocol: 2 g of the total RNA isolated from the M cell, FAE, VAE and PPL samples were reverse transcribed using the R&D Systems cDNA labeling kit (R&D Systems, Oxon, UK) in the presence of [-33P]-dCTP (Amersham Life Science).  Briefly, the RNA and mouse cytokine-specific primers (provided with kit) were first denatured at 90C for 2 minutes, incubated at 42C for 20 minutes and then the reagents for reverse transcription were added.  Each reverse transcriptase (RT) reaction contained RT buffer, dNTP mix (333 M dATP, dGTP, dTTP, 1.67 M dCTP), 20U/ml of RNasin (Promega, Southampton, UK), 50 U AMV reverse transcriptase and [-33P]-dCTP, 20 Ci, 2000-3,000 Ci/mmol.  The RT reaction was allowed to proceed for 2 Hours at 42C.  Removal of unincorporated nucleotide was achieved by the use of Sephadex G-25 spin column.

extract_protocol: Total RNA was extracted and DNAse-I treated using the Absolutely RNA RT-PCR Miniprep kit (Stratagene, LaJolla, CA, USA) following the procedure followed provided by the  manufacturer.  The total RNA samples were then analyzed by electrophoresis in a 1.5% 1X TBE agarose gel (Sigma) and visualized by ethidium bromide (Sigma) staining under UV light.  Total RNA was quantified using a GeneQuant II spectrophotometer (Amersham-Pharmacia, Buckinghamshire, UK).  Absorbance readings were taken at 260 nm and 280 nm and the concentration and the ratios determined.

treatment_protocol:
Isolation of Peyer’s patch lymphocytes

Following enzymatic digestion, as described above, the patches were compressed between 2 sterile glass slides and the resulting cell suspension was filtered through a 30-m filter and viability determined as described above. The cells were then incubated in 200 l with 10 l of FITC-CD45 antibody (IQ products, Groningen, The Netherlands) for 15 minutes. The cell–antibody complex was then processed using the MACS columns and the anti-FITC microbeads, as described above, and the positive and negative fractions were analyzed by Flow cytometry (as above). These CD45 positive cells were denoted as Peyer’s patch lymphocytes (PPL).

tag: BALB/C

tag: Female


title: UEA-ve FAE

scan_protocol: The screens were then scanned at 50-m pixel size using a STORM phosphorimager (Molecular Dynamics).

data_processing: The normalized data was then imported to Microsoft Excel (Microsoft, Ireland), where the ratios of differences between the samples of interest were calculated.  The normalized data was also analyzed using Cluster and TreeView (Michael Eisen, Stanford University, USA).  Using Cluster, the array data was filtered; log transformed, median centered and hierarchically clustered and visualized using TreeView.  The Cluster transformed data was also analyzed using J-Express software (MolMine AS, Bergen, Norway) to evaluate common gene expression trends.  Gene lists were complied and the function of the genes of interest were determined using Genecards (http://bioinformatics.weizmann.ac.il/cards-bin/carddisp?[gene) and the PubMed database (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed).

source_name: UEA-ve FAE isolated form Peyer's patches

treatment_protocol:
Following cervical dislocation, the small intestine was carefully removed from the duodenum to the caecum. Areas of the intestine containing Peyer’s patches were removed, and dissected longitudinally using a Stereo Dissecting Microscope (Olympus, Middlesex, UK); the surrounding non-Peyer’s patch epithelium was removed. The Peyer’s patch was placed in an enzymatic digest solution (250 U/ml of Hyaluronidase (Sigma, Dorset, UK), 1 U/ml of Dispase I (Roche Diagnostics, East Sussex, UK) in Ca2+/Mg2+ free 1X PBS (Gibco BRL, Paisley, UK) for 30 minutes, shaking at 37C.  Following digestion, the supernatant containing FAE and lymphocytes was removed and centrifuged for 10 minutes at 200g.  The cell isolate was then resuspended in DMEM (25 mM glucose) 10% FCS (Gibco BRL), supplemented with Fungizone (2.5 g/ml) (Gibco BRL).

Isolation of UEA1 positive M cells

The FAE cell digest was incubated in 0.01% EDTA (Sigma) for 15 minutes and then passed through a 30-m filter (Miltenyi Biotech, Surrey, UK), to remove cell aggregates. Cell viability was assessed and the cells were centrifuged (200g x 10 min) and resuspended in 1X PBS with 0.5% BSA (Sigma) and 2 mM EDTA (Sigma). The cells were then incubated, in 200l, for 30 minutes at room temperature with FITC-UEA1 lectin (40 g/ml) (Vector Laboratories, Burlingame, CA, USA). The cell suspension was then washed twice in PBS (0.5% BSA, 2mM EDTA), by centrifugation and resuspended in 90 l, and incubated with 10 l of MACS anti-FITC Microbeads (Miltenyi Biotech) at 4C for 15 minutes. The cell-bead suspension was then washed by centrifugation (300g x 10 minutes) and the cell-bead complex resuspended in 500 l of degassed PBS (0.5% BSA, 2mM EDTA). The cell-bead suspension was then applied to a MACS MS+ selection column (Miltenyi Biotech) in the presence of the MiniMACS high-energy permanent magnet (Miltenyi Biotech).  The negative (non FITC-UEA1 binding) cells were allowed to flow through the column. The column was washed 5 times with the degassed PBS solution and the fractions pooled with the negative cells. The magnet was then removed and the positive (FITC-UEA1 binding) cells were flushed out of the column. Both positive (M cell) and negative samples (FAE) were enumerated for viability and enrichment using trypan blue counting and the Beckman-Coulter Epics elite (CEE) cell sorter (Oxford, UK) to measure fluorescence and forward scatter (granularity) of the samples

tag: female


title: VAE

source_name: Purified villus associated enterocytes

treatment_protocol:
Isolation of Small Intestinal Epithelium

Peyer’s patches were removed from the intestinal segments which were then dissected longitudinally and digested in a Trypsin (0.25%)/EDTA (0.02%) solution (Gibco BRL) for 30 minutes shaking at 37C. The cell suspension was then centrifuged (200g x 10 min), resuspended in DMEM (10% FCS).  The small intestinal digest prepared was filtered and incubated with FITC-CD45 antibody. The sample was incubated with anti-FITC microbeads and MACS column, as described above, with the epithelial population being isolated by negative selection. This epithelial population was denoted as the villus-associated epithelium (VAE).


title: 5202764005790181113004.E03

description: MCF7 with vehicle (DMSO) for 6 h


status: Public on Sep 25 2006

type: genomic

city: Bunkyo-ku

first: Katsuhiko

last: Shirahige

state: Tokyo

address: 1-1-1 Yayoi

department: Research Center for Epigenetic Disease

institute: The University of Tokyo

description: SUP fraction used for normalization of Hrr25 (GSM108201 and GSM108202).

data_processing: The protocol provided by Affymetrix (GCOS ver1.4) was used.

molecule: genomic DNA

organism: Saccharomyces cerevisiae

source_name: Sup fraction (equal to Whole cell extract DNA)

tag: Strain SK1 was used.


title: M cell, purified UEA+ve FAE epithelia

hyb_protocol: The 33P cDNA probes from the samples of interest were hybridized overnight at 65C to the Mouse Cytokine Expression Array Version 1.0 (Sigma-R&D Systems).  The cDNA arrays were then washed three times with 0.5X SSPE/1%SDS (low stringency) and twice at 65C with 0.1 X SSPE/1%SDS (high stringency). The arrays were then exposed to a phosphorimaging screen (Molecular Dynamics, Amersham Biosciences, UK) overnight.

data_processing: Phoretix Array2 Software (Nonlinear Dynamics, Newcastle-upon-Tyne, UK) was used to analyze the array images.  The images were background subtracted and the intensity normalized to negative controls and to the selected housekeeping gene, beta-actin.  The normalized data was then imported to Microsoft Excel (Microsoft, Ireland), where the ratios of differences between the samples of interest were calculated.  The normalized data was also analyzed using Cluster and TreeView (Michael Eisen, Stanford University, USA).  Using Cluster, the array data was filtered; log transformed, median centered and hierarchically clustered and visualized using TreeView.  The Cluster transformed data was also analyzed using J-Express software (MolMine AS, Bergen, Norway) to evaluate common gene expression trends.  Gene lists were complied and the function of the genes of interest were determined using Genecards (http://bioinformatics.weizmann.ac.il/cards-bin/carddisp?[gene) and the PubMed database (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed).

source_name: purified M cells from FAE isolated above murine Peyer's patches


title: 5202764005790181113004.G02

description: MCF7 with vehicle (DMSO) for 6 h


title: 5202764005790181113004.H02

description: MCF7 treated with rottlerin (.00001 M) for 6 h

value: rottlerin


title: 5202764005790181113004.H01

description: MCF7 with vehicle (DMSO) for 6 h


title: BW25113 ycfR deletion mutant LB glu 15hr biofilm cells

status: Public on Sep 26 2006

city: College Station

first: Rodolfo

middle: Garcia

last: Contreras

email: Rodolfo.Garcia@chemail.tamu.edu, Xuesong.Zhang@chemail.tamu.edu, Thomas.Wood@chemail. tamu.edu

state: TX

address: Room 502 Jack E. Brown building 3122 TAMU

department: Chemical Engineering

institute: Texas A and M University

description: RNA extracted from biofilm cells of E. coli K12 ycfR deletion mutant after 15 hours of growth in LB glu with glass wool

data_processing: MAS 5.0 Expression Analysis Default Setting

organism: Escherichia coli

source_name: Channel 1


title: Hrr25 distribution in Meiosis (mam1 deletion mutant)

description: Hrr25 distribution in meiosis I in the absence of Mam1.

source_name: Chromatin-immunoprecipitated DNA

tag: Strain SK1 was used (mam1 was disrupted). Hrr25 was tagged by 9XMyc.


title: Ral for 48h A

city: Urbana

first: Jonna

last: Frasor

state: IL

department: Molecular and Integrative Physiology

institute: University of Illinois

description: 1uM Raloxifene-treated 48h sample, set A


title: Hrr25 distribution in Meiosis

description: Hrr25 distribution in meiosis I.

tag: Strain SK1 was used. Hrr25 was tagged by 9XMyc.


title: TOT for 8h B

description: 1uM TOT-treated 8h sample, set B


title: Ral for 8h A

description: 1uM Raloxifene-treated 8h sample, set A


title: TOT for 48h B

description: 1uM TOT-treated 48h sample, set B


title: ICI for 48h B

description: 1uM ICI-treated 48h sample, set B


title: Oxyntic mucosa_LAR-vehicle_21-days_rep1

city: Trondheim

first: Sten

middle: Even

last: Erlandsen

address: Olav Kyrres gate 9, 5 etg.

department: Department of Cancer Research and Molecular Medicine

country: Norway

institute: NTNU

description: RNA from eigth animals (controls that received the LAR-vehicle) were pooled to produce a control affymetrix chip. Six animals (treatmentgroup) were given octreotide LAR and RNA from two and two animals were pooled to produce tree affymetrix chips to compare to the controlchip.

hyb_protocol: Hybridization was performed in accordance with the standard array format protocol using 15µg fragmented biotinylated cRNA. The hybridization cocktails were applied to the arrays and left to hybridize at 45°C for 16 hours in an Affyetrix GeneChip Hybridization oven 640 with constant rotation (60rpm). The chips were washed and stained using Affymetrix Fluidic Station 400 controlled by MicroArray Suite 5.0. The antibody amplification protocol EukGE-WS2v4 (Affymetrix) was used for controlling the washing and staining. Staining was performed using streptavidin phycoerythrin (SAPE, Molecular Probes, Eugene, Oregon, USA), followed by adding biotinylated antibody (Vector Laboratories) to streptavidin and then one more time with streptavidin phycoerythrin.

scan_protocol: The arrays were scanned using Agilent GeneArray Scanner.

data_processing: Scanner controlled by MAS.

label: Biotin

organism: Rattus norvegicus

source_name: Oxyntic mucosa, octreotide LAR, 21 days.

label_protocol:
Biotin-labeled cRNA synthesis:  IVT Labeling Kit (Affymetrix)
Biotin-labeled cRNA clean up: GeneChip® Sample Cleanup Module (Affymetrix).

growth_protocol: Tissue were put into liquid nitrogen at once after separation from the rats.

extract_protocol: Extraction of total RNA were done using RNeasy Midi Kit (Qiagen, Vanlencia, CA)

treatment_protocol: Rats housed in wire-mesh cages at 20-24°C with constant humidity and a 12:12 h light-dark cycle, and fed ad libitum with a commercial rat diet and tap water. Overnight (one night) fast the animals were anesthetised with 0.4 ml per 100 g body weight of a combination of (per ml) 0.02 mg fentanyl, 0.02 mg haloperidol and 2 mg midazolam. Eight animals received the LAR vehicle in corresponding volume to 5 mg/animal of Octreotide LAR.

tag: Sprague-Dawley, female, 8 weeks, mean body weight 212.4 g (range 193-227). Tissue

value: scraped off gastric mucosa (corpus).


title: BW25113 w/t LB glu 15hr biofilm cells

description: RNA extracted from biofilm cells of E. coli K12 wild type after 15 hours of growth in LB glu with glass wool


title: Ral for 8h B

description: 1uM Raloxifene-treated 8h sample, set B


title: ICI for 8h B

description: 1uM ICI-treated 8h sample, set B


title: TOT for 8h A

description: 1uM TOT-treated 8h sample, set A


title: Oxyntic mucosa_Octreotide LAR_21-days_rep2

source_name: Oxyntix mucosa, Octreotide LAR, 21 days

tag: Sprague-Dawley, female, 8 weeks. Tissue

value: scraped off oxyntic mucosa.


title: TOT for 48h A

description: 1uM TOT-treated 48h sample, set A


title: ICI for 48h A

description: 1uM ICI-treated 48h sample, set A


title: Mam1 distribution in Meiosis

description: Mam1 distribution in meiosis I.

tag: Strain SK1 was used. Mam1 was tagged by 3XFLAG.


title: Oxyntic mucosa_Octreotide LAR_21-days_rep1


title: ICI for 8h A

description: 1uM ICI-treated 8h sample, set A


title: tac1-1D leaf replicate 2

status: Public on Sep 23 2006

first: Thomas

middle: D.

last: McKnight

address: 3258 TAMU

department: Biology

institute: Texas A&M University

description: Replicate #2 of tac1-1D, an activation tagged line over-expressing TELOMERASE ACTIVATOR 1, a small zinc-finger transcription factor (Ren et al., 2004. Plant Cell 16; 2910-2922)

hyb_protocol: Standard Affymetrix Protocol

scan_protocol: Affy GeneChip Scanner 3000.

data_processing: MAS 5.0 (GCOS v1.3), scaled to 500

source_name: Leaves from 3 week old plants grown in growth chamber

label_protocol: Standard Affymetrix Protocol

growth_protocol: Plants were harvested after 3 weeks growth in a growth chamber (16hr/8 hr light/dark cycle; 21C/18C temperature cycle; 70% relative humidity).

extract_protocol: Triazol

tag: tac1-1D 3 week old leaves


title: Oxyntic mucosa_Octreotide LAR_21-days_rep3


title: tac1-1D leaf replicate 1

description: Replicate #1 of tac1-1D, an activation tagged line over-expressing TELOMERASE ACTIVATOR 1, a small zinc-finger transcription factor (Ren et al., 2004. Plant Cell 16; 2910-2922)


title: tac1-1D leaf replicate 3

description: Replicate #3 of tac1-1D, an activation tagged line over-expressing TELOMERASE ACTIVATOR 1, a small zinc-finger transcription factor (Ren et al., 2004. Plant Cell 16; 2910-2922)


title: wild type (Columbia) leaf replicate 3

description: Replicate #3 of wild type control for comparison to tac1-1D, an activation tagged line over-expressing TELOMERASE ACTIVATOR 1, a small zinc-finger transcription factor (Ren et al., 2004. Plant Cell 16; 2910-2922)

tag: Columbia ecotype 3 week old leaves


title: wild type (Columbia) leaf replicate 2

description: Replicate #2 of wild type control for comparison to tac1-1D, an activation tagged line over-expressing TELOMERASE ACTIVATOR 1, a small zinc-finger transcription factor (Ren et al., 2004. Plant Cell 16; 2910-2922)


title: wild type (Columbia) leaf replicate 1

description: Replicate #1 of wild type control for comparison to tac1-1D, an activation tagged line over-expressing TELOMERASE ACTIVATOR 1, a small zinc-finger transcription factor (Ren et al., 2004. Plant Cell 16; 2910-2922)


title: B-CLL sample BB23, poor prognosis

status: Public on Sep 22 2006

city: Essen

first: Ludger

last: Klein-Hitpass

address: Virchowstr. 173

department: Universitaetsklinikum

country: Germany

institute: Institut fuer Zellbiologie

description: Aim: to compare the transcriptosomes of good prognosis CLL cases (ZAP-70-CD38-) to poor prognosis cases (ZAP-70+CD38+). Methods: Immunomagnetic isolation was done using MidiMacs resulting in >95% purity of leukemic cells as detected by FACS analysis of CD19+CD5+ cells. The leukemic cells were freshly purified from untreated patients and RNA was directly isolated from fresh cells without further ex vivo treatment of the cells.Eight immunomagnetically purified peripheral blood derived  ZAP-70+CD38+ CLL cases were compared with eight ZAP-70-CD38- B-CLL cases.

hyb_protocol: Following fragmentation, 10 microg of cRNA were hybridized for 16 hr at 45C on HG-U133A Arrays. GeneChips were washed and stained in the Affymetrix Fluidics Station 400.

scan_protocol: GeneChips were scanned using the Hewlett-Packard GeneArray Scanner G2500A.

data_processing: The data were analyzed with Microarray Suite version 5.0 (MAS 5.0) using Affymetrix default analysis settings and global scaling as normalization method. The trimmed mean target intensity of each array was arbitrarily set to 1000.

source_name: immunomagnetically purified fresh CD19+ peripheral blood CLL cells

label_protocol: Biotinylated cRNA were prepared according to the standard Affymetrix protocol from 6 microg total RNA (Expression Analysis Technical Manual, 2001, Affymetrix).

growth_protocol: no in vitro culture

extract_protocol: Isolation of total RNA was performed with QIAGEN Rneasy columns according to the manufacturer's instructions.

treatment_protocol: no treatment

tag: immunomagnetically purified native B-CLL cells from the peripheral blood of untreated patients


title: B-CLL sample 690, poor prognosis


title: B-CLL sample 783, good prognosis


title: B-CLL sample 1087, poor prognosis


title: B-CLL sample 705, good prognosis


title: B-CLL sample 844, poor prognosis


title: B-CLL sample 777, poor prognosis


title: A549 cell line – exposure 3 Cobalt 2mM – 24h - replicate1

city: bagnols sur ceze

first: Bérenguer

last: Frédéric

department: SBTN

institute: CEA/DSV

description: Control sample from A549 cells was labelled in Cy5 and hybridized against Cobalt sample labelled in Cy3

data_processing: Ratios (test/control) were normalized towards the mean ratio of the microarray then converted to base-2 logarithms

source_name: A549 cell line – 2mM Cobalt – 24h

tag: Cobalt sample from A549 cells

source_name: A549 cell line – 0mM Cobalt – 24h

tag: Control sample from A549 cells


title: B-CLL sample 638, poor prognosis


title: B-CLL sample 838, poor prognosis